



**The 3rd Quadrennial Meeting of the
World Federation of Neuro-Oncology**
jointly with
**The 6th Meeting of the
Asian Society for Neuro-Oncology (ASNO)**

The 3rd WFNO
with
The 6th ASNO
Yokohama 2009



CONTENTS

INVITATION	3
ORGANIZING COMMITTEE	4
SCIENTIFIC BOARD	4
PROGRAM COMMITTEE	4
LOCAL ORGANIZING COMMITTEE	5
GENEROUS SUPPORT	6
ACCESS	8
VENUE	8
ROOM LOCATION	9
POSTER LAYOUT	10
MEETING INFORMATION	11
ANCILLARY MEETING	11
SOCIAL PROGRAMS	12
INSTRUCTIONS FOR PRESENTATION	14
PROGRAM AT A GLANCE	16
PROGRAM	18
ABSTRACTS	49
AUTHOR'S INDEX	245

INVITATION

Dear Friends and Colleagues:

It is our great pleasure and honor to welcome you to the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) to be held jointly with the 6th Meeting of the Asian Society for Neuro-Oncology (ASNO) in Yokohama, Japan on May 11-14, 2009.

The World Federation of Neuro-Oncology decided to hold a scientific meeting organized by three international societies for neuro-oncology, the Society for Neuro-Oncology (SNO) in U.S.A., the European Association of Neurooncology (EANO) in Europe, and the Asian Society for Neuro-Oncology (ASNO) in Asia, every 4 years. The first meeting was held in Washington, DC, U.S.A. in 2001, the second was in Edinburgh, U.K. in 2005, and the third will be hosted by our Asian Society for Neuro-Oncology in Japan.

We are putting together an attractive program consisting of an educational symposium on May 11, which will be suitable for post-graduates and those wishing to learn about updates on recent progress in neuro-oncology. The opening ceremony followed by a welcome reception will be held in the late afternoon on May 11. The main scientific program will start on May 12 and will include a wide variety of topics in the fields of diagnosis, treatment, and biology of brain tumors. During the lunch time, we will prepare "luncheon seminars" to focus on special fields of neuro-oncology, special techniques for treating patients, or newly developing treatment modalities.

Yokohama is an international port city next to Tokyo, and it is, therefore, a very convenient place from Tokyo train station (30min.) and from Tokyo (Narita) International Airport (90 min.). Yokohama has developed as the base for foreign trade in Japan since 1859, and it is one of the very few cities in Japan with a diverse multicultural population with multicultural festivals and events. Yokohama is an ideal place for exchanging information and ideas freely with your colleagues from all over the world.

We look forward to meeting you in Yokohama, and to discussing our accomplishments and plans for the future of neuro-oncology.

Sincerely,



Masao Matsutani, M.D., D.M.Sci.

President

*The 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology
and the 6th Meeting of the Asian Society for Neuro-Oncology*

Director

*Saitama International Medical Center & Comprehensive Cancer Center
Saitama Medical University, Japan*

■ORGANIZING COMMITTEE

President:

Masao Matsutani (Saitama Medical University International Medical Center, Japan)

Vice President:

Susan Chang (University of California, San Francisco, USA)

Kyung Gi Cho (Azou University, Korea)

Michael Weller (University Hospital Zurich, Switzerland)

■SCIENTIFIC BOARD

Susan Chang (University of California, San Francisco, USA)

Jonathan Finlay (Childrens Hospital Los Angeles & University of Southern California, USA)

Abhijit Guha (University of Toronto, Canada)

Erwin van Meir (Emory University School of Medicine, USA)

Michael Vogelbaum (Cleveland Clinic, USA)

Lorenzo M. Bello (University of Milan, Italy)

Beatrice Malmer (Umeå University, Sweden)

Jeremy Rees (Institute of Neurology Queen Square London, UK)

Avelina Tortosa (Universitat de Barcelona, L'Hospitalet de Llobregat, Spain)

Michael Weller (University Hospital Zurich, Switzerland)

Kaya Aksoy (Uludag University, School of Medicine, Turkey)

Kyung Gi Cho (Azou University, Korea)

Masao Matsutani (Saitama Medical University International Medical Center, Japan)

Shin-Ichi Miyatake (Osaka Medical College, Japan)

Ryo Nishikawa (Saitama Medical University International Medical Center, Japan)

Soichiro Shibui (National Cancer Center, Japan)

Tay-Tong Wong (Taipei Veterans General Hospital, Taiwan)

Liang-Fu Zhou (Shanghai Huashan Hospital, China)

■PROGRAM COMMITTEE

Kaya Aksoy (Uludag University, School of Medicine, Turkey)

Lorenzo M. Bello (University of Milan, Italy)

Rolf Bjerkvig (University of Bergen, Norway)

Oliver Bogler (University of Texas MD Anderson Cancer Center, USA)

Eric Bouffet (The Hospital for Sick Children, Canada)

Mitchel Burger (University of California, San Francisco, USA)

Susan Chang (University of California, San Francisco, USA)

Shi-Yuan Cheng (University of Pittsburgh Cancer Institute, USA)

Antonio Chiocca (The Ohio State University Medical Center, USA)

Lisa DeAngelis (Memorial Sloan-Kettering Cancer Center, USA)

Jonathan Finlay (Childrens Hospital Los Angeles & University of Southern California, USA)

Takamitsu Fujimaki (Saitama Medical University, Japan)

Toshihiko Iuchi (Chiba Cancer Center, Japan)

Beatrice Malmer (Umeå University, Sweden)

Shin-Ichi Miyatake (Osaka Medical College, Japan)

Ryo Nishikawa (Saitama Medical University International Medical Center, Japan)

Hideho Okada (University of Pittsburgh Cancer Institute, USA)
 Stephen Sands (Columbia University Medical Center, USA)
 Hideyuki Saya (Institute for Advanced Biosciences, Keio University, Japan)
 Yuta Shibamoto (Nagoya City University, Japan)
 Soichiro Shibui (National Cancer Center, Japan)
 Minoru Suzuki (Kyoto University Research Reactor Institute, Japan)
 Jeremy Rees (Institute of Neurology Queen Square London, UK)
 Avelina Tortosa (Universitat de Barcelona, L'Hospitalet de Llobregat, Spain)
 Erwin van Meir (Emory University School of Medicine, USA)
 Michael Vogelbaum (Cleveland Clinic, USA)
 Michael Weller (University Hospital Zurich, Switzerland)
 Tai-Tong Wong (Taipei Veterans General Hospital, Taiwan)
 Takaaki Yanagisawa (Saitama Medical University International Medical Center, Japan)
 W. K. Alfred Yung (University of Texas MD Anderson Cancer Center)

■LOCAL ORGANIZING COMMITTEE

Norio Arita (Hyogo College of Medicine, Japan)
 Akio Asai (Kansai Medical University, Japan)
 Takamitsu Fujimaki (Saitama Medical University, Japan)
 Takamasa Kayama (Yamagata University, Japan)
 Masato Kohchi (Oita San-ai Medical Center, Japan)
 Toshihiro Kumabe (Tohoku University, Japan)
 Junichi Kuratsu (Kumamoto University, Japan)
 Kaoru Kurisu (Hiroshima University, Japan)
 Masao Matsutani (Saitama Medical University International Medical Center, Japan)
 Shin-Ichi Miyatake (Osaka Medical College, Japan)
 Ryo Nishikawa (Saitama Medical University International Medical Center, Japan)
 Takanori Ohnishi (Ehime University, Japan)
 Yutaka Sawamura (Hokkaido University, Japan)
 Hideyuki Saya (Institute for Advanced Biosciences, Keio University, Japan)
 Soichiro Shibui (National Cancer Center, Japan)
 Kazuhiko Sugiyama (Hiroshima University, Japan)
 Jun Takahashi (Kitano Hospital, Japan)
 Hideo Takeshima (Miyazaki University, Japan)
 Toshihiko Wakabayashi (Nagoya University, Japan)
 Jun Yoshida (Nagoya University, Japan)
 Toshiki Yoshimine (Osaka University, Japan)

Secretary General

Ryo Nishikawa (Saitama Medical University International Medical Center, Japan)

Secretariat

Takamitsu Fujimaki (Saitama Medical University, Japan)
 Takaaki Yanagisawa (Saitama Medical University International Medical Center, Japan)

■ GENEROUS SUPPORT

Generous support for this Meeting has been provided by the following foundations, associations, societies, companies and hospitals with deepest appreciation.

SPONSORED BY:

Japan Brain Foundation
Pediatric Brain Tumor Foundation

The Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ)

Alfresa Pharma Corporation	Nippon Chemiphar Co.,Ltd.
Asahi Kasei Pharma Corporation	Nippon Kayaku Co.,Ltd.
Aska Pharmaceutical Co.,Ltd.	Nippon Shinyaku Co.,Ltd.
Astellas Pharma Inc.	Nippon Zoki Pharmaceutical Co.,Ltd.
AstraZeneca PLC	Nipro Pharma Corporation
Banyu Pharmaceutical Co.,Ltd.	Novartis Pharma K.K.
Bayer Yakuhin	Ono Pharmaceutical Co.,Ltd.
Bristol-Myers K.K.	Otsuka Pharmaceutical Co.,Ltd.
Chugai Pharmaceutical Co.,Ltd.	Otsuka Pharmaceutical Factory, Inc.
Daiichi Sankyo Co.,Ltd.	Pfizer Japan Inc.
Dainippon Sumitomo Pharma Co.,Ltd.	Rohto Pharmaceutical Co.,Ltd.
Eiken Chemical Co.,Ltd.	Sanofi-Aventis K.K.
Eisai Co.,Ltd.	Santen Pharmaceutical Co.,Ltd.
Elmed Eisai Co.,Ltd.	Sanwa Kagaku Kenkyusho Co.,Ltd.
Fuso Pharmaceutical Industries, Ltd.	Sato Pharmaceutical Co.,Ltd.
GlaxoSmithKline K.K.	Sawai Pharmaceutical Co.,Ltd.
Japan Tobacco Inc.	Schering-Plough K.K.
Kaken Pharmaceutical Co.,Ltd.	Shionogi & Co.,Ltd.
Kaken Shoyaku Co.,Ltd.	SSP Co.,Ltd.
Kissei Pharmaceutical Co.,Ltd.	Taiho Pharmaceutical Co.,Ltd.
Kowa Shinyaku Co.,Ltd.	Taisho Pharmaceutical Co.,Ltd.
Kracie Holdings,Ltd.	Takeda Bio Development Center Limited.
Kyorin Pharmaceutical Co.,Ltd.	Takeda Pharmaceutical Co.,Ltd.
Kyowa Hakko Kirin Co.,Ltd.	Teijin Pharma Limited
Maruho Co.,Ltd.	Terumo Corporation
Maruishi Pharmaceutical. Co.,Ltd.	Toa Eiyo Pharmaceutical Company
Meiji Seika Kaisha Ltd.	Torii Pharmaceutical Co.,Ltd.
Minophagen Pharmaceutical Co.,Ltd.	Towa Pharmaceutical Co.,Ltd.
Mitsubishi Tanabe Pharma Corporation	Toyama Chemical Co.,Ltd.
Mochida Pharmaceutical Co.,Ltd.	Tsumura & Co.
Mylan Inc.	Wakamoto Pharmaceutical Co.,Ltd.
Nihon Pharmaceutical Co.,Ltd.	Wyeth Lederle Japan,Ltd.
Nippon Boehringer Ingelheim Co.,Ltd.	Yakult Honsha Co.,Ltd.

Others:

Asamoto Clinic	Motobu Noge Hospital
Bishinkai Kurosawa Hospital	Nagashima Nogeika Clinic
Hannou Seiwa Hospital	Nakamura Memorial Hospital
Harada Clinic	Obitsu Sankei Hospital
Helios Society Hospital	Ohbayashi Clinic
Keijinkai Hospital	Ohkawara Neurosurgical Hospital
Kitamura Neurosurgery Clinic	Sougo Minami-Tohoku Hospital
Matsumiya Noshinkeigeka Clinic	Suzuki Neurosurgical Clinic
Minamisunamachi Clinic	Yamamoto Maeda Memorial Hospital
Mitaka Nakamura Noshinkeigeka Clinic	Yoseikai Teraoka Memorial Hospital
Moriyama Memorial Hospital	

SUPPORTED BY:

American Family Life Assurance Company of Columbus
Ark Therapeutics Ltd.
Carl Zeiss Meditec Co., Ltd.
Chugai Pharmaceutical Co., Ltd.
Daiichi-Sankyo Co., Ltd.
Eisai Co., Ltd.
Fujita Medical Instruments Co., Ltd.
Johnson & Johnson K.K.
Merck Serono
Mitsubishi Tanabe Pharma Corporation
NAKANISHI INC.
NovoCure Ltd.
ONO & CO., LTD.
Olympus Medical Systems Corp.
SBI ALA PROMO Co., Ltd.
Schering-Plough
Specified Nonprofit Corporation Gold Ribbon Network
Toray Medical Co., Ltd.




EXHIBITORS:

Ark Therapeutics Ltd.
Cell-Medicine, Inc.
Children's Cancer Association of Japan (CCAJ)
Elekta K.K.
International Brain Tumour Alliance (IBTA)
Leica Microsystems K.K.
Medical Publisher Service
Merck Serono
ONO & CO., LTD.
Pediatric Brain Tumor Foundation
Schering-Plough
Society for Neuro-Oncology
Specified Nonprofit Corporation Gold Ribbon Network
Yoshida Manufacturing Co., Ltd.


(in alphabetical order)

as of April 24, 2009

ROOM LOCATION



POSTER LAYOUT



Program	Poster Number	Area
Stem Cell Science	P001–P006	Poster Viewing 1 Room 301+302
Surgery for Malignant Glioma	P007–P022	
Immunology	P023–P025	
Gene Therapy	P026–P027	
Pediatric Neuro-Oncology I	P028–P040	
Hoshino Award Selection	P041–P067	
Basic Science I, Genome - Proteome	P068–P076	
Stem Cell Science Posters	P077–P088	
Diagnostic Radiology	P089–P102	
Novel Treatment Approach	P103–P105	
Glioma	P106–P113	
Metastatic Brain Tumors	P114–P119	
Epidemiology	P120	
Poster Presentations: Neurosurgery	P121–P126	Poster Viewing 2 Room 311+312
Poster Presentations: Neurosurgery	P127–P167	
Temozolomide and MGMT	P168–P179	
Angiogenesis and Anti-Angiogenesis Therapy	P180–P184	
Chemotherapy, Molecular-Targeted Therapy	P185–P214	Poster Viewing 3 Room 313+314
Pediatric Basic Science I	P215–P220	
Cognitive Function and Outcome	P221–P224	
Poster Presentations: Basic Science	P225–P252	Poster Viewing 4 Foyer
Poster Presentations: Basic Science	P253–P294	
Radiation Oncology	P295–P311	
Primary Central Nervous System Lymphoma	P312–P318	

MEETING INFORMATION

Registration Desk

The Registration Desk is located on the 2nd floor of the PACIFICO YOKOHAMA.

The Registration Desk will open at the following times:

May 10 (Sun) 15:00-18:00

May 11 (Mon) 10:00-21:00

May 12 (Tue) 07:30-18:00

May 13 (Wed) 07:30-18:30

May 14 (Thu) 07:30-18:00

Travel Desk

The Travel Desk will be located next to the Registration Desk to assist you with any transportation questions you might have. Also, if you are interested in sightseeing information, changing flight departure dates or general travel information, please direct your inquiries to the Travel Desk.

Name Tags

Name Tags are mandatory for access to all Scientific Sessions, the Commercial Exhibits and Social Programs.

- Accompanying persons will not be allowed in the Scientific Sessions.
- Exhibitors will not be allowed except in Exhibition unless you have paid the Meeting registration fee.
- Seminar/Symposium sponsors will not be allowed except in your own sponsored programs unless you have paid the Meeting registration fee.
- Access to all programs will be strictly controlled; therefore, please wear your Meeting Name Tags at all times.

Internet Access

Internet access is available during this meeting. It is located on the 3rd floor in the lobby and Exhibition areas.

Secretariat Office

Will open during this meeting 3F, Room 315

Tel: 045-228-6392

Hands-On Seminar

Date: Tuesday, May 12

Time: 11:00-13:00

Venue: 3F, Lounge, PACIFICO YOKOHAMA

Registration: **May 11 (Mon)** 10:00-21:00, Registration Desk (2F)

May 12 (Tue) 07:30-10:00, Registration Desk (2F)

10:00-11:00, In front of the Lounge (3F)

Limited number of attendance: 80 people

Note: 32 people will be able to have experience in operations on who registered on a first-come, first-served basis.

Safety and Security

Please do not leave bags unattended at any time, whether inside or outside session. Hotels strongly recommend that you use their safety deposit boxes for your valuables.

ANCILLARY MEETING

May 11 (Mon)

ASNO Business Meeting (invited members only)

Time: 13:00-14:00

Venue: 2F, Room 211 + 212, PACIFICO YOKOHAMA

■ SOCIAL PROGRAMS

● Opening Ceremony

Date: May 11 (Mon)
Time: 18:00-18:30
Venue: 1F, Main Hall, PACIFICO YOKOHAMA
Fee: Free

● Charity Concert

Date: May 11 (Mon)
Time: 18:30-19:30
Venue: 1F, Main Hall, PACIFICO YOKOHAMA

Special notes: 1. The concert will be open to the public. Hence, there will be a limited number of seats available due to selling tickets at a price of JPY2,000 on a first-come-first served basis on that day.
2. The proceeds from the concert will be donated to Children's Cancer Association of Japan (CCAJ) and to Pediatric Brain Tumor Foundation (PBTF) in the USA.

● Welcome Reception

Date: May 11 (Mon)
Time: 19:40-21:30
Venue: 3F, Lounge, PACIFICO YOKOHAMA
Fee: Free (included in the registration fee)

● Meeting Dinner

Date: May 12 (Tue)
Time: 19:00-21:00
Venue: 3F, Ball Room, InterContinental Yokohama Grand
Fee: Free (included in the registration fee)

● Banquet

Date: May 13 (Wed)
Time: 19:00-21:00
Venue: B2, Ball Room, Pan Pacific Yokohama Bay Hotel Tokyu
Menu: French cuisine (macrobiotic food carefully selected ingredients by Grand Chef Toshinori Sogabe)
Fee: ¥10,000

● Accompanying Persons' Programs

Optional Sightseeing Tour and Culture Program

Wednesday, May 13

Time: 09:00-16:30
Price: ¥12,000 per person
Sightseeing tour to Kamakura, the ancient capital city of Japan, to visit The Great Image of Buddha (Daibutsu), designated as a National Treasure.

Thursday, May 14

Culture program/demonstration which you can enjoy a hands-on experience of Japanese culture.

Time: 10:00-17:00
Venue: 3F, Lounge, PACIFICO YOKOHAMA
Price: Free

Program/demonstration:

You can take your work home as a souvenir

1. Origami (the traditional Japanese art of paper folding)
2. Japanese Calligraphy (the art of Japanese words)
3. Nigaoe (have your portrait sketched)
4. NioiBukuro (making fragrance bags, made of the material of the kimono)

◆ Post Meeting Tour

For details and applications, ask at the Travel Desk

Friday, May 15

Time: 07:30-17:00

Price: ¥13,000 per person

Sightseeing tour to Mount Fuji 5th Station

Enjoy a bus tour to the fifth station of Mt. Fuji and experience the beautiful view from the 5th station.

Notes: 1. This tour will take you to the 5th station of Mt. Fuji not to the summit. It is officially open for climbing only during summer from July to September, where Mount Fuji (Fujisan) is Japan's highest mountain at 3,776 meters.

2. Tour may be cancelled when the participants are under 20 persons.

● Hoshino Award Selection and Ceremony

Presentation by selected candidates

May 13 (Wed) 08:00-09:30

Venue: 1F, Main Hall, Room 1

Selection of Winners and Announcement

May 13 (Wed) 14:00

The winners will be posted on the board at the Poster Registration on the 3rd Floor and congratulated ribbons are put on the winners' posters.

Award Ceremony

May 13 (Wed) 18:30-18:45

Venue: 1F, Main Hall, Room 1

Personal History of Dr. Hoshino

Professor Takao Hoshino was the pioneer of cell kinetics of brain tumor. He continued his work on brain tumor research until he passed away from gastric cancer at the age of 55.

He is one of the founding members of the Japan Society for Neuro-oncology together with Professor Masakatsu Nagai, which later became one of the cores of the Asian Society for Neuro-oncology (ASNO).

He was born and grown up in Tokyo, graduated from the University of Tokyo in 1962 to get M.D. He started his career as a neurosurgeon to join the Department of Neurosurgery just founded by Professor Keiji Sano. The Department was the first Neurosurgical Department in Japan and he is the "firstborn" to Professor Keiji Sano. In 1964, during his stay in Israel, he encountered with a molecule called bromodeoxyuridine (BrdU, BUdR) which is an analogue of thymidine. He found that this molecule has a radiosensitized effect on cells and he invented a new therapy called BAR therapy of malignant brain tumors. BrdU, which was injected into the carotid artery was incorporated into the nuclei of the tumor cells during their DNA synthesis. During irradiation therapy, this incorporated BrdU works as a radiosensitizer to the tumor cells. With this therapy a number of patients with malignant brain tumor survived better. Although the treatment did not spread widely because of the limitation of technology, i.e. catheter or infusion pump of that time, the concept per se was a really an innovative one.

Dr. Hoshino got his D.M.Sc. in 1973 from the University of Tokyo and soon became research fellow at the University of California, San Francisco for three years. After his stay in the UCSF, he occasionally got faculty positions in the University of Tokyo or Tokyo Metropolitan Komagome Hospital, but mostly stayed in the faculty position in UCSF. He finally headed the Brain Tumor Research Center of UCSF as a full professor until he came back to Japan as a Professor in Neuro-oncology, Kyorin University in 1989.

During his research work, he realized that brain tumor cells are not just stay on glass slide as "pathology specimens" but they are dynamic biological phenomena in human body. He tried to analyze the movement of cells or "cell kinetics" of tumor cells initially labeling S-phase cells by tritiated thymidine, by which we can tell which cells are dividing cells under microscope. Interestingly, in this cell kinetics field, the molecule BrdU re-appeared on-stage in 1980th. The technique of monoclonal antibody was invented and anti-BrdU monoclonal antibody was available now. He injected BrdU before removal of the malignant tumors, then stained the surgical specimen with anti-BrdU monoclonal antibody to detect the dividing cells. His 10 years research in this field yielded vast knowledge on dynamics or cell kinetics of malignant brain tumors, especially gliomas.

Since his work on neuro-oncology was so wide, it is difficult to mention all of them in a limited space. It is for sure that with his work, the brain tumor became a dynamic vivid existence from static phenomenon under glass slides. With these advancement of knowledge of brain tumors, the treatment strategy to brain tumors has been advanced remarkably.

He had been a good friend of Professor Charles B. Wilson, the former Chairman of the Department of Neurosurgery, UCSF and also of Professor Victor Levin of Neurooncology, UCSF and MD Anderson Cancer Center. He trained many neuro-oncologists around the world including many Asian exchange scientists. Professor Masao Matsutani was also influenced a lot from Dr. Hoshino when Masao was junior to Takao at Tokyo Metropolitan Komagome Hospital.

Dr. Hoshino served as an editor or a reviewer for many academic journals including Journal of Neuro-oncology, Cancer Research, Journal of Neurosurgery, Neurosurgery and so on. He published more than 197 articles in various academic journals.

He was awarded with Anne and Jason Farber Award from the American Academy of Neurology 1990 for his long-lasting outstanding contribution in neuro-oncology field.

Although he was diagnosed to have advanced gastric cancer on 1987, his enthusiasm for research never faded away until his last day. He endured two surgeries and many hard chemotherapy protocols, without stopping his research career. He served as a president for the Annual Meeting of the Japan Society for Neuro-oncology in November 1992. During the meeting, although he was wearing a jacket for central venous line, he made many comments and questions with his usual piercing eyes. However the final day came at last and he passed away January 28th, 1993.

To memorize his achievements in neuro-oncology and to encourage young investigators, a fund was established and Hoshino Award was given to young investigators every year at the Japan Society for Neuro-oncology since 1993.

■ INSTRUCTIONS FOR PRESENTATION

I. Disclosure of Conflicts of Interest

The 3rd WFNO/the 6th ASNO is committed to ensuring the integrity of its scientific, educational, and research programs and offering the best continuing medical education in neuro-oncology. Disclosure of conflicts of interest helps maintain the integrity of the information presented at the 2009 WFNO/ASNO meeting. To help support this effort, WFNO/ASNO requires that all meeting presenters honor the WFNO/ASNO Conflict-of-Interest Policy. This policy requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict.

Additionally, WFNO/ASNO abides by rules formulated by the Accreditation Council for Continuing Medical Education (ACCME), which require presenters to disclose possible conflicts both verbally and in writing. As a presenter, this means you must disclose any relevant financial relationships you or your spouse/partner has had within the past 12 months. For this purpose, “relevant financial relationships” are those from which you or your spouse/partner have received or may receive financial benefit and which are related to annual meeting CME content.

By submitting a disclosure, you agree that you have read WFNO/ASNO Conflict-of-Interest Policy and understand and support its intent. To ensure full disclosure and proper preparation of your presentation, please review the following information according to your presentation format (PowerPoint or Poster).

PowerPoint Presentations

WFNO/ASNO rules session chairs and speakers to include conflict-of-interest disclosure slides in their presentations and inform audiences of any conflicts verbally. In addition, WFNO/ASNO requires its faculty to disclose to the audience any discussion of off-label use of a drug or medical device in their presentation. This promotes transparency and understanding in practice. If these requirements are not met, the presentation may be stricken from the program.

When preparing your PowerPoint presentation, be sure to include a disclosure slide immediately after your title slide. If you have nothing to disclose, a statement to that effect, “There are no relevant conflicts of interest to disclose,” should be included on the slides and stated in your presentation, consisting of 1st slide: Title; 2nd slide: Conflict-of-interest disclosure slide; 3rd slides ~ Presentation contents.

Poster Presentations

First authors must list conflicts of interest for themselves and all co-authors on the bottoms of the poster.

If an author has nothing to disclose, his or her statement should read, “I have not relevant conflicts of interest to disclose.” If none of the authors of the absence have relevant conflicts of interest to disclose, the statement should read, “There are no relevant conflicts of interest to disclose,” to be followed in the same manner as described above.

II. Instructions for ORAL Presentation


Clarity of slides is vital for a successful scientific presentation.

1. All the speakers are requested to keep to the time previously allotted for each.
Green and **Orange** lamps will tell you how much time is remaining in your presentation. A green lamp will indicate when one minute remains, while an orange will light up when no time remains.
2. All presentations will be done on PC.
3. Please bring your own PC and a backup of your data.
The only PC media that will be available are CD-R, DVD-R, or USB.
4. PCs with Windows XP and PowerPoint 2003 are to be used.
PCs with Macintosh OS X and PowerPoint 2004 are to be used.
Windows Vista/Macintosh users: Please bring your own computer for your presentation.
5. Animation and sound functions will be available. If your presentation data is in PC media, please make sure that the data is compatible with Media Players for Windows or Quick Time for Macintosh. Standard PC fonts (for Windows or Macintosh) should be used.

6. If you are using your own PC, please make sure to bring an AC adaptor (standard 2-pin type). For projector output purposes, a VGA cable will be provided. Please confirm whether your PC is equipped with an RGB jack (mini D-sub 15 pin type) as standard. If you use a different type of RGB jack to connect to an external monitor, please bring it with you. XGA (1024x768) is the suitable monitor size. For purpose data projection, please adjust your screen setting to XGA. Please cancel your screen saver and power saving settings in advance, especially if your data includes video image and sound.
7. Please bring your PC or PC data to the PC Preview Center located in the 1F Lobby at least 30 minutes prior to your presentation to register and submit it to test the connection and view your file. If you are delayed, we will inform the chairperson of your session who will postpone your presentation for a few minutes if necessary.
8. Those who bring your PPT presentation on CD-R, DVD-R, or USB, after you have checked your data; please bring it to the Presentation Room by yourself for data backups.
Those who bring your own PC, after you have checked your data, please bring it to the Operation Desk located in front of the Presentation Room. After your presentation, your PC will be back to you.
9. Please use the mouse and keyboard on the podium for your presentation. You are required to handle your data yourself, using the mouse and keyboard connected to the PC.
10. The copied data for your presentation will be deleted by the secretariat after the meeting.

RGB jack

Mini D-sub 15 pin



III. Instructions for POSTER Presentation

Presenters should prepare four (4) slides for platform presentation in addition to the conflict-of-interest disclosure slide and poster.

1. Poster

Presenters are requested to follow the schedule below when mounting your poster on the assigned board and removing your poster materials from the board.


Set-up: May 12 07:30-12:00

Remove: May 14 17:00-18:00

Posters: **90cm wide x 180cm high**

Your poster presentation number will be posted on your assigned board.

Posters are still mounted after 18:00, these will be deleted by the Secretariat.



2. Platform Presentation

Please prepare 5 slides for platform presentation as described below. The presentation will be allocated a 3-minute time slot. Presentations are conducted in the Platform Presentation Room.

1st slide: Title slide

2nd slide: Conflict-of-interest disclosure slide

3rd – 5th slides: Presentation contents

Please refer to the section (I) above for the poster creation method.

PROGRAM AT A GLANCE

May 11 (Mon) Previous Day					
Lobby (2F)	Room 1 Main Hall (1F)	Room 2 303 (3F)	Room 3 304 (3F)	Lounge (3F)	Poster Viewing & Exhibition 301+302 (3F)
7:00					
8:00					
9:00					
10:00					
11:00		Registration			
12:00		Educational Lectures			
13:00					
14:00					
15:00					
16:00	Registration				
17:00					
18:00	Opening Ceremony Charity Concert				
19:00					
20:00				Welcome Reception	
21:00					

May 12 (Tue) 1st Day					
Lobby (2F)	Room 1	Room 2	Room 3	Lounge (3F)	Poster Viewing & Exhibition
7:00	Main Hall (1F)	303 (3F)	304 (3F)		301+302 (3F)
8:00					
9:00	Stem Cell Science	Surgery for Malignant Glioma	Pediatric Neuro-Oncology I		
10:00					
11:00	Invited Lecture	Special Seminar		Hands-On Seminar Skull Base Technique	Poster Viewing & Exhibition
12:00	Lunchtime Seminar	Lunchtime Symposium	Lunchtime Symposium		
13:00	Role of Surgery in The Treatment of Malignant Brain Tumors				
14:00		Invited Lecture	Lectures Open to the Public		
15:00	Evening Symposium	Immunology			
16:00		Gene Therapy			
17:00					
18:00					
19:00	Meeting Dinner at InterContinental Yokohama Grand				
20:00					
21:00					

May 13 (Wed) 2nd day					
Lobby (2F)	Room 1 Main Hall (1F)	Room 2 303 (3F)	Room 3 304 (3F)	Lounge (3F)	Poster Viewing & Exhibition 301+302 (3F)
7:00					
8:00	Hoshino Award Selection	Diagnostic Radiology	Glioma		Poster Viewing & Exhibition
9:00			Metastatic Brain Tumors		
10:00	Basic Science I, Genome-Proteome				
11:00	Lecture from SNO	Novel Treatment Approach	Strategies for Management of Patients with Brain Tumors in Emerging Countries		
12:00	Lunchtime Seminar	Lunchtime Seminar			
13:00	Lecture from EANO	Basic Science II	Epidemiology		
14:00			Sellar/Parasellar Lesions		
15:00	Ongoing Clinical Trials and the Future Direction of Glioma Treatment		Meningioma, Chordoma		
16:00			Poster Presentations, Neurosurgery		
17:00	Special Lecture				
18:00	Stem Cell Science Posters				
19:00		Hoshino Award Ceremony			
20:00	Banquet at Pan Pacific Yokohama Bay Hotel Tokyu				
21:00					

	May 14 (Thu) 3rd Day					
	Lobby (2F)	Room 1	Room 2	Room 3	Lounge (3F)	Poster Viewing & Exhibition
7:00		Main Hall (1F)	303 (3F)	304 (3F)		301+302 (3F)
8:00	Registration					
9:00		Temozolomide and MGMT	Pediatric Basic Science I	Poster Presentations: Basic Science		Poster Viewing & Exhibition
10:00		Angiogenesis and Anti-Angiogenesis Therapy	Pediatric Neuro-Oncology II			
11:00		Lecture from ASNO				
12:00		Lunchtime Symposium	Lunchtime Seminar	Lunchtime Symposium	Japanese Culture Program	
13:00		Chemotherapy, Molecular-Targeted Therapy	Cognitive Function and Outcome	Radiation Oncology		
14:00			Pediatric Basic Science II	Primary Central Nervous System Lymphoma		
15:00						
16:00						
17:00						
18:00		Closing Ceremony				
19:00						
20:00						
21:00						

PROGRAM

May 11 (Mon) 303+304 *previous day

●Educational Lectures: Treatment of Malignant Brain Tumors

Chairperson: Takamitsu Fujimaki (*Japan*)

Introduction

- | | |
|-------|--|
| 11:00 | GERM CELL TUMOR
Takamitsu Fujimaki (<i>Japan</i>) |
| 11:20 | PEDIATRIC BRAIN TUMOR (MEDULLOBLASTOMA, EPENDYMOMA, CHOROID PLEXUS PAPILLOMA)
Mark W. Kieran (<i>USA</i>) |
| 11:50 | PREVENTION AND/ OR MANAGEMENT OF ADVERSE EVENTS, SUPPORTIVE CARE
Irene Slavic (<i>Austria</i>) |

Lunch

Chairpersons: Susan Chi (*USA*)
Yasushi Ino (*Japan*)

- | | |
|-------|--|
| 13:05 | LECTURE ON NEUROPATHOLOGY
Andreas von Deimling (<i>Germany</i>) |
| 13:35 | MOLECULAR PATHOGENESIS
Koichi Ichimura (<i>UK</i>) |
| 14:00 | NEUROIMAGING (PET, MRI)
Sarah Nelson (<i>USA</i>) |
| 14:25 | GLIOBLASTOMA
Mark R. Gilbert (<i>USA</i>) |
| 14:50 | LOW GRADE DIFFUSE ASTROCYTOMA
Susan Chang (<i>USA</i>) |
- Break**
- | | |
|-------|---|
| 15:25 | OLIGODENDROGLIOMA
Keisuke Ueki (<i>Japan</i>) |
| 15:45 | METASTATIC BRAIN TUMOR
Gabriele Schackert (<i>Germany</i>) |
| 16:10 | NEW AGENTS, MOLECULAR TARGETING THERAPY
Clifford Schold (<i>USA</i>) |
| 16:30 | PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Antonio Omuro (<i>USA</i>) |

May 11 (Mon) Room 1

- | | |
|-------|--------------------------------|
| 18:00 | Opening Ceremony |
| 18:30 | Charity Concert |
| 19:40 | Welcome Reception (3F, Lounge) |

May 12 (Tue) Room 1

●Stem Cell Science

Chairpersons: Sin-Soo Jeun (*Korea*)
Manfred Westphal (*Germany*)

- | | | |
|-------|-------------|---|
| 08:00 | P001 | CD133: STILL A MARKER OF BRAIN TUMOR STEM CELLS?
Xuqun Tang (<i>China</i>) |
| 08:03 | P002 | CD133 NEGATIVE GLIOMA SUBPOPULATIONS GROUPED BY DIFFERENT CELL TYPE MARKERS
DISPLAY TUMORGENICITY IN VIVO.
Per Oyvind Enger (<i>Norway</i>) |

- 08:06 **P003** NOVEL TECHNIQUE FOR ESTABLISHMENT OF GLIOBLASTOMA STEM CELL LINE AND PATHOLOGICAL VERIFICATION OF DISTRIBUTION AND DIFFERENTIATION STAGE OF TUMOR CELLS ON ITS XENOGRFT.
Koichi Yoshikawa (*Japan*)
- 08:09 **P004** THERAPEUTIC EFFECT OF GENETICALLY ENGINEERED MESENCHYMAL STEM CELLS IN RAT EXPERIMENTAL LEPTOMENINGEAL GLIOMA MODEL
Chunyu Gu (*Japan*)
- 08:12 **P005** CHLOROQUINE SUPPRESSES GLIOMA CELL VIABILITY AND SENSITIZES RADIORESISTANT STEM-LIKE GLIOMA CELLS TO IONIZING RADIATION AND CHEMOTHERAPY
Ella L. Kim (*Germany*)
- 08:15 **P006** ESTABLISHMENT AND CHARACTERIZATION OF AN EXPERIMENTAL MODEL OF INVASIVE GLIOMA WITH HIGHLY RADIORESISTANT PHENOTYPE.
Ella L. Kim (*Germany*)
- 08:25 **O001** NG2 EXPRESSION ESTABLISHES A LINK BETWEEN NEURAL PRECURSORS AND CANCER STEM CELLS IN GLIOBLASTOMA
Talal M. Fael Al-Mayhami (*UK*)
- 08:55 **O002** A SINGLE CD133-POSITIVE CELL IS CAPABLE OF PRODUCING GLIOMA POPULATION DIVERSITY
Akio Soeda (*USA*)
- 09:05 **O003** ANALYSIS OF CANCER STEM CELLS IN GENETICALLY-INDUCED BRAIN TUMORS
Hideyuki Saya (*Japan*)
- 09:15 **O004** GLIOMA STEM CELLS ARE INVOLVED IN TUMOR TISSUE REMODELING IN XENOGRFT MODEL
Jun Dong (*China*)
- 09:25 **O005** ENDOTHELIAL CELLS AND DIFFERENTIATED TUMOR CELLS FUNCTION AS A STEM NICHE TO GLIOBLASTOMA STEM-LIKE CELLS BY PROVIDING NOTCH LIGANDS
Xing Fan (*USA*)
- 09:35 **O006** AN ESSENTIAL ROLE OF C-MET/HGF SIGNALING IN GLIOBLASTOMA INITIATING CELLS
Do-Hyun Nam (*Korea*)
- 09:45 **O007** DEVELOPMENT AND APPLICATIONS OF STEM CELL BASED PRE-CLINICAL MODELS OF GLIOMAS
Deepak Kamnasaran (*Canada*)
- 09:55 **O008** IN VIVO TRACKING SPIO LABELLED MESENCHYMAL STEM CELL TROPISM TOIN VIVO TRACKING NANOPARTICLE-LABELLED STEM CELL TROPISM TO BRAIN MALIGNANT GLIOMA AFTER SYSTEMATICAL INJECTION BY A CLINICAL 1.5T MR
Jianhong Zhu (*China*)
- 10:05 **O009** P53 INDEPENDENT ABROGATION OF G1 ARREST IN MURINE BRAIN TUMOR-DERIVED STEM LIKE CELLS AFTER IONIZING RADIATION
Cynthia Wetmore (*USA*)
- 10:15 **O010** ANGIOGENESIS OF GLIOMAS: VASCULAR TUBE FORMATION FROM TRANSDIFFERENTIATION OF GLIOMA STEM/PROGENITOR CELLS.
Qiang Huang (*China*)
- 10:25 **O011** DUAL-TARGETED ANTITUMOR EFFECTS AGAINST BRAINSTEM GLIOMA BY INTRAVENOUS DELIVERY OF TRAIL GENE TRANSFERED STEM CELLS
Jian-Hong Zhu (*China*)
- 10:35 **O012** ALTERED EXPRESSION OF MICRORNA CLUSTERS IS ASSOCIATED WITH THE STEMNESS PROFILE OF GLIOMAS
Iris Lavon (*Israel*)

●Invited Lecture

Chairperson: Hideyuki Saya (*Japan*)

- 11:00 **IL01** STEM CELLS AND CANCER STEM CELLS
Toshio Suda (*Japan*)

●Lunchtime Seminar: High Grade Glioma: The Emergence of Gene Medicines

Sponsored by Ark Therapeutics Ltd.

Chairperson: Manfred Westphal (*Germany*)

- 12:00 **LSe01** GENE MEDICINES FOR THE TREATMENT OF HGG
Zvi Ram (*Israel*)
- 12:30 **LSe02** SITIMAGENE CERADENOVEC: PHASE III CLINICAL TRIAL RESULTS
Manfred Westphal (*Germany*)

●Role of Surgery in The Treatment of Malignant Brain Tumors

Sponsored by Johnson & Johnson K.K.

Chairpersons: Lorenzo M. Bello (*Italia*)
Kyung Gi Cho (*Korea*)
Yuanli Zhao (*China*)

- 13:00 **O013** THE ROLE OF SURGERY IN THE MANAGEMENT OF PEDIATRIC BRAIN TUMORS
Mark M. Souweidane (*USA*)
- 13:30 **O014** SURGERY OF SUPRATENTORIAL PEDIATRIC BRAIN TUMORS
Gabriele Schackert (*Germany*)
- 14:00 **O015** SURGICAL RESECTION STRATEGIES FOR OPTIMIZING GLIOMA REMOVAL
Mitchel S. Berger (*USA*)
- 14:30 **O016** GLIOMA SURGERY, ITS ADVANCEMENTS, PROBLEMS AND FUTURE
Takamasa Kayama (*Japan*)

●Evening Symposium: Temozolomide, New Aspects

Sponsored by Schering-Plough

Chairperson: W.K. Alfred Yung (*USA*)

- 15:10 **ES01** MOLECULAR CHARACTERISTIC OF LGG
W.K. Alfred Yung (*USA*)
- 15:40 **ES02** PROGNOSIS AND THE ROLE IMAGING IN PROGNOSTIC PREDICTION IN LGG
Martin van den Bent (*Netherlands*)
- 16:10 **ES03** WHEN TO DECIDE RESECTION IN LGG
Toshihiro Kumabe (*Japan*)
- 16:40 **ES04** ROLE OF CHEMOTHERAPY IN MANAGEMENT OF LGG
Michael Prados (*USA*)

May 12 (Tue) Room 2

●Surgery for Malignant Glioma

Chairpersons: Chun Kee Chung (*Korea*)
Christianto Lumenta (*Germany*)
Keisuke Ueki (*Japan*)

- 08:00 **P007** FUNCTIONAL RESULTS AFTER RESECTION OF GLIOMA INVOLVING THE SUPPLEMENTARY MOTOR AREA
Takeo Uzuka (*Japan*)
- 08:03 **P008** THE DIAGNOSTIC IMPACT OF RADICAL RESECTION IN THE MANAGEMENT OF LOW-GRADE GLIOMA
Yoshiki Arakawa (*Japan*)
- 08:06 **P009** EXPERIENCE WITH SPECTROSCOPY-SUPPORTED STEREOTACTIC BRAIN BIOPSY
Mikhail Chernov (*Japan*)
- 08:09 **P010** USEFULNESS OF FDG-PET-CT-GUIDED STEREOTACTIC BIOPSY FOR BRAIN TUMORS
Satoshi Horiguchi (*Japan*)
- 08:12 **P011** NEURONAVIGATION AND BRAIN BIOPSY. SURGICAL TECHNIQUE AND COMPARISON WITH TRADITIONAL ESTEREOTAXIC METHOD.
Jesus Merino (*Spain*)
- 08:15 **P012** THE ROLE OF DIFFUSION TENSOR IMAGE OF THE TUMOR RESECTION
Chi-tun Tang (*Taiwan*)
- 08:18 **P013** USEFULNESS OF FIBER TRACT NAVIGATION IN TUMOR SURGERY ADJACENT TO ELOQUENT AREA
Seung Hwan Lee (*Korea*)
- 08:21 **P014** PREOPERATIVE FUNCTIONAL IMAGING AND INTRAOPERATIVE MONITORING FOR IMPROVING RESECTION RATE OF GLIOMAS AND FUNCTIONAL OUTCOME OF THEIR PATIENTS
Katsushi Taomoto (*Japan*)
- 08:24 **P015** AWAKE CRANIOTOMY AND ELECTROPHYSIOLOGICAL MAPPING IN A HIGH FIELD INTRA-OPERATIVE MRI
Ian F. Parney (*USA*)
- 08:27 **P016** NEW INTRAOPERATIVE MRI SYSTEM IN BRAIN TUMOR SURGERY
Kaori Sakurada (*Japan*)

- 08:30 **P017** NOVEL SURGICAL TECHNIQUE OF RADICAL REMOVAL FOR GLIOMAS
Kyung Gi Cho (*Korea*)
- 08:33 **P018** DISSECTION AND SEPARATION OF HIGH GRADE GLIAL TUMORS FROM BRAIN TISSUE BY USING METHALIC DISSECTOR WITH THE CAPABILITY OF PRODUCING VIBRATION
Cengiz Cokluk (*Turkey*)
- 08:36 **P019** THE OPERATION OF PIAL SYNANGIOSIS IN THE SURGICAL TREATMENT OF MALIGNANT GLIAL TUMORS
Cengiz Cokluk (*Turkey*)
- 08:39 **P020** THE CLINICAL RESULTS OF FIVE CASES OF INSULAR TUMOR RESECTION
Chun Kee Chung (*Korea*)
- 08:42 **P021** KEYHOLE SURGERY IN THE TREATMENT OF GLIOMAS
Toshihiko Iuchi (*Japan*)

Keynote

- 08:50 **KN01** SURGERY ON PATIENTS WITH SYMPTOMATIC LOW GRADE GLIOMA IN CRITICAL BRAIN AREA
Christianto Lumenta (*Germany*)
- 09:20 **O017** AWAKE SURGERY DURING RESECTION OF INSULAR GLIOMAS
Ruben Dammers (*Netherlands*)
- 09:30 **O018** AWAKE CRANIOTOMY FOR THE PRESERVATION OF THE BRAIN FUNCTIONS INCLUDING LANGUAGE, MOTOR, AND HIGHER BRAIN FUNCTIONS
Kuniaki Saito (*Japan*)
- 09:40 **O019** CRANIAL SURGERY AND NAVIGATION BY USING LOW-FIELD-STRENGTH INTRAOPERATIVE MAGNETIC RESONANCE IMAGING: EXPERIENCE IN 251 PATIENTS
Cancelled
- 09:50 **O020** DEVELOPMENT OF THE COMPACT MAGNETIC RESONANCE IMAGING SYSTEM FOR INTRAOPERATIVE IMAGING.
Akio Morita (*Japan*)
- 10:00 **O021** PRESURGICAL PLANNING FOR CEREBRAL GLIOMA WITH PYRAMIDAL TRACT INVOLVEMENT IN A STEREOSCOPIC DTI-BASED VIRTUAL REALITY ENVIRONMENT
Qiu Tianming (*China*)
- 10:10 **O022** ROLE OF DTI FIBER TRACKING IN PREDICTING THE EXTENT OF RESECTION IN GLIOMA SURGERY
Giorgio Carrabba (*Italia*)
- 10:20 **O023** OPTICAL COHERENCE TOMOGRAPHY FOR INTRAOPERATIVE ANALYSIS OF GLIOMA TISSUE MICROSTRUCTURE AND LIGHT ATTENUATION AS A NOVEL TECHNIQUE TO CONTROL THE EXTENT OF RESECTION
Alf Giese (*Germany*)

●Special Seminar: 5-ALA

Sponsored by SBI ALA PROMO Co., Ltd.

Chairperson: Soichiro Shibui (*Japan*)

- 10:45 **IL02** GLIOLAN IN THE THERAPY OF MALIGNANT GLIOMAS: QUO VADIS?
Walter Stummer (*Germany*)
- 11:45 **P022** SIGNIFICANCE OF PORPHYRINS IN BLOOD AND URINE OF BRAIN TUMOR PATIENTS THAT UNDERWENT 5-ALA ADMINISTRATION
Satoshi Utsuki (*Japan*)

●Lunchtime Symposium: Targeting Integrins in Glioblastoma Treatment

Sponsored by Merck Serono

Chairpersons: Roger Stupp (*Switzerland*)
Yong-Kwang Tu (*Taiwan*)

- 12:00 **LSy01** WELCOME AND INTRODUCTION
Yong-Kwang Tu (*Taiwan*)
- 12:10 **LSy02** GLIOBLASTOMA AND CURRENT TREATMENT MODALITIES
Michael Weller (*Switzerland*)
- 12:25 **LSy03** INTEGRINS: NOVEL TARGETS IN GLIOBLASTOMA TREATMENT
Joerg-Christian Tonn (*Germany*)
- 12:45 **LSy04** PRE-CLINICAL PROOF OF PRINCIPLE FOR INTEGRIN INHIBITORS IN GLIOBLASTOMA TREATMENT
Tom Mikkelsen (*USA*)
- 13:05 **LSy05** TARGETED GLIOBLASTOMA THERAPIES: INTERACTIVE CASE STUDIES
David A. Reardon (*USA*)

- 13:30 **LSy06** ONGOING CLINICAL TRIALS
Roger Stupp (*Switzerland*)
- 13:45 **LSy07** DISCUSSION AND CLOSING REMARKS
Roger Stupp (*Switzerland*)

●Invited Lecture

Chairperson: Hideho Okada (*USA*)

- 14:10 **IL03** ENGINEERING T CELLS FOR ADOPTIVE THERAPY
Carl June (*USA*)

●Immunology

Chairpersons: Jun-ichi Kuratsu (*Japan*)
Ryuya Yamanaka (*Japan*)

- 15:10 **O024** SYSTEMIC INHIBITION OF TRANSFORMING GROWTH FACTOR β IN GLIOMA-BEARING MICE IMPROVED THE THERAPEUTIC EFFICACY OF PEPTIDE VACCINATIONS TARGETING GLIOMA-ASSOCIATED ANTIGENS
Ryo Ueda (*USA*)
- 15:20 **O025** INTERFERON- α SIGNALING IN THE BRAIN PLAYS A MAJOR ROLE IN IMMUNE SURVEILLANCE DURING GLIOMA-GENESIS IN MICE
Mitsugu Fujita (*USA*)
- 15:30 **O026** AUTOLOGOUS DENDRITIC CELLS-BASED IMMUNOTHERAPY FOR MALIGNANT GLIOMAS- A PHASE II PROSPECTIVE RANDOMIZED CLINICAL TRIAL
Der-Yang Cho (*Taiwan*)
- 15:40 **O027** PHASE II CLINICAL TRIAL OF WT1 VACCINATION AGAINST RECURRENT GLIOBLASTOMA WITH ANALYSES OF WT1 SPECIFIC CYTOTOXIC T LYMPHOCYTES
Naoya Hashimoto (*Japan*)
- 15:50 **O028** PHASE I/IIA TRIAL OF AUTOLOGOUS FORMALIN FIXED TUMOR VACCINE IN TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME.
Yoshihiro Muragaki (*Japan*)
- 16:00 **O029** TYPE-1 DENDRITIC CELL VACCINES IN COMBINATION WITH POLY-ICLC - ASSOCIATION BETWEEN POSITIVE TETRAMER RESPONSE AND 6-MONTH PROGRESSION-FREE SURVIVAL
Hideho Okada (*USA*)
- 16:20 **P023** ELECTROLOADED DENDRITIC CELLS WITH WHOLE TUMOR LYSATE ELICIT ENHANCED INDUCTION OF TUMOR-SPECIFIC IFN γ PRODUCING CELLS IN PATIENTS WITH GLIOBLASTOMA
Shusuke Moriuchi (*Japan*)
- 16:23 **P024** CYTOTOXIC T LYMPHOCYTES INDUCTION WITH HLA-A2402-RESTRICTED GLIOMA SPECIFIC PEPTIDES
Hidemitsu Sato (*Japan*)
- 16:26 **P025** CHARACTERIZATION OF A NOVEL TUMOR-ASSOCIATED ANTIGEN FOR TARGETED TOXIN THERAPY IN GLIOMAS.
Oscar Persson (*Sweden*)

●Gene Therapy

Chairpersons: Takashi Tamiya (*Japan*)
Tomoki Todo (*Japan*)

Keynote

- 16:30 **KN02** THE ROLE OF MICRORNAS IN MALIGNANT GLIOMA
Antonio Chiocca (*USA*)
- 17:00 **O176** TREATMENT OF OPERABLE HIGH-GRADE GLIOMA WITH SITIMAGENE CERADENOVEC GENE THERAPY AND GANCICLOVIR: RESULTS OF A RANDOMIZED PHASE III TRIAL
Zvi Ram (*Israel*)
- 17:20 **O030** INDUCIBLE ONCOLYTIC TRANSFORMATION OF REPLICATION-DEFICIENT VIRUS FOR THE CELL-BASED VIROTHERAPY
Hiroshi Nakashima (*USA*)
- 17:30 **O031** ONCOLYTIC VIRUS THERAPY OF GLIOMA SENSITIZES GLIOMA CELLS TO CILENGITIDE TREATMENT.
Kazuhiko Kurozumi (*USA*)
- 17:40 **P026** TUMORICIDAL BYSTANDER EFFECT-MEDIATED SUICIDE GENE THERAPY OF GLIOMA USING GENETICALLY ENGINEERED BONE MARROW-DERIVED MESENCHYMAL STEM CELLS
Shinji Amano (*Japan*)

17:43 **P027** AN EFFICIENT TARGETED GENE THERAPY USING BRAIN TUMOR-SPECIFIC PROMOTER
Toshio Yawata (*Japan*)

May 12 (Tue) Room 3

●Pediatric Neuro-Oncology I

Chairperson: Takaaki Yanagisawa (*Japan*)

- 08:00 **P028** LONG-TERM OUTCOME OF 23 CONSECUTIVE CHILDREN WITH PRIMARY INTRADURAL SPINAL TUMORS TREATED AT THE MEDICAL UNIVERSITY OF VIENNA (1997-2008)
Thomas Czech (*Austria*)
- 08:03 **P029** EFFECTIVENESS OF MULTI-STAGED OPERATIONS WITH COMBINED CHEMOTHERAPIES FOR HUGE MALIGNANT INFANTILE BRAIN TUMORS IN THE FIRST YEAR OF LIFE
Naoki Kagawa (*Japan*)
- 08:06 **P030** WHICH THERAPY WORKS BETTER IN METASTATIC CHOROID PLEXUS CARCINOMAS?
Su G Berrak (*Turkey*)
- 08:09 **P031** 99 TC SESTAMIBI SCAN DIFFERENTIATES TUMOR FROM OTHER CONTRAST ENHANCING TISSUE IN CHOROID PLEXUS TUMORS - CASE REPORT AND REVIEW OF LITERATURE
Vivek Subbiah (*USA*)
- 08:12 **P032** ADJUVANT CHEMORADIATION FOR MIXED GERM CELL TUMORS
Yuji Uematsu (*Japan*)
- 08:15 **P033** OVER A 10-YEAR SURVIVAL AND COMPLETE RESPONSE OF A PATIENT WITH DIFFUSE INTRINSIC BRAINSTEM GLIOMA (DBSG) TREATED WITH ANTINEOPLASTONS (ANP)
Robert A. Weaver (*USA*)
- 08:18 **P034** IMPROVED RESPONSE OF PONTINE GLIOMA WITH SIMULTANEOUS RADIOCHEMOTHERAPY: RESULTS OF A RETROSPECTIVE IMAGE ANALYSIS
Liunan Li (*USA*)
- 08:21 **P035** TACTICS FOR DIAGNOSIS AND SURGICAL TREATMENT OF BRAIN STEM TUMORS
Qianxue Chen (*China*)
- 08:24 **P036** PROFILE OF PATIENTS WITH MEDULLOBLASTOMA AT THE PHILIPPINE GENERAL HOSPITAL: A SIX-YEAR REVIEW
Jessie T. Colacion (*Philippines*)
- 08:27 **P037** RESULTS OF TREATMENT FOR MEDULLOBLASTOMA IN OUR INSTITUTE
Naoyuki Ohe (*Japan*)
- 08:30 **P038** CAN ABSOLUTE LYMPHOCYTE COUNT REALLY BE A PROGNOSTIC INDICATOR FOR OVERALL SURVIVAL IN PATIENTS WITH MEDULLOBLASTOMA?
Digvijaya D. Navalkele (*USA*)
- 08:33 **P039** INTEGRATING COMPLEXITY, THERAPEUTIC RECREATION, AND RADIOTHERAPY IN MULTIDISCIPLINARY MEDICAL TEAM ON REDUCING ANESTHESIA/SEDATION REQUIREMENT FOR TODDLERS AND YOUNG CHILDREN WITH BRAIN TUMOR
I-Tsun Chiang (*Taiwan*)
- 08:36 **P040** IMPLICATIONS OF COMPLEXITY: LEISURE PARTICIPATION ON PRIMARY CAREGIVERS AND HOSPITALIZED CHILDREN WITH BRAIN TUMOR
I-Tsun Chiang (*Taiwan*)

Break

Chairpersons: Byung-Kyu Cho (*Korea*)
Thomas Czech (*Austria*)
Tai-Tong Wong (*Taiwan*)

- 08:50 **O032** MEDULLOBLASTOMA : THE ROLE OF TOTAL TUMOR REMOVAL TO AVOID RECURRENCE
Eka Wahjoepramono (*Indonesia*)
- 09:00 **O033** OPTIMIZING THE PHYSICAL AND BIOLOGICAL PARAMETERS OF RADIOTHERAPY IN AVERAGE-RISK MEDULLOBLASTOMA
Tejpal Gupta (*India*)
- 09:10 **O034** DO MEDULLOBLASTOMAS IN ADOLESCENTS HAVE A DISTINCT MOLECULAR SIGNATURE & DIFFERENT TUMOR BIOLOGY?
Wan-Yee Teo (*USA*)

- 09:20 **O035** AUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH HIGH RISK BRAIN TUMORS
Ho Joon Im (*Korea*)
- 09:30 **O036** CLINICOPATHOLOGICAL FEATURES OF ATYPICAL TERATOID/RHABDOID TUMORS: ITS DIAGNOSIS AND TUMOR GROWTH FACTOR
Hidehiro Oka (*Japan*)
- 09:40 **O037** PRE-CLINICAL TESTING OF COMBINATION RADIATION PLUS HISTONE DEACETYLASE INHIBITOR THERAPY IN TREATING ATYPICAL TERATOID RHABDOID TUMOR
Rintaro Hashizume (*USA*)
- 09:50 **O038** ATYPICAL CHOROID PLEXUS PAPILLOMA: 2008 INTERIM ANALYSIS OF THE CPT-SIOP-2000 STUDY
Johannes E.A. Wolff (*USA*)
- 10:00 **O039** METASTATIC CHOROID PLEXUS TUMORS - DATA OF THE CPT-SIOP-2000 STUDY
Johannes E.A. Wolff (*USA*)
- 10:10 **O040** PEDIATRIC GLIOSARCOMAS: CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS
Michael Karremann (*Germany*)
- 10:20 **O041** ROLE OF TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED DIFFUSE BRAINSTEM GLIOMA IN CHILDREN- EXPERIENCE IN A SINGLE INSTITUTION
Kuo-Liang Chiang (*Taiwan*)
- 10:30 **O042** ROLE OF SURGERY FOR OPTIC PATHWAY/HYPOTHALAMIC ASTROCYTOMAS IN CHILDREN
Yutaka Sawamura (*Japan*)
- 10:40 **O043** PROGNOSTIC ANALYSIS OF 220 PATIENTS WITH INTRAMEDULLARY SPINAL CORD EPENDYMOMAS
Guihuai Wang (*China*)
- 10:50 **O044** GRADING SYSTEM FOR DIAGNOSIS AND TREATMENT OF INTRACRANIAL NONGERMINOMATOUS MALIGNANT GERM CELL TUMORS
Xiang Huang (*China*)
- 11:00 **O045** OPTIMAL TREATMENT STRATEGY FOR INTRACRANIAL GERM CELL TUMORS: SINGLE INSTITUTION ANALYSIS.
Masayuki Kanamori (*Japan*)
- 11:10 **O046** THE OPTIMAL RADIATION VOLUME AND DOSE FOR INTRACRANIAL GERMINOMA
Yi-Wei Chen (*Taiwan*)
- 11:20 **O047** GERM CELL TUMORS IN THE BASAL GANGLIA: CLINICAL OUTCOMES AND DIAGNOSTIC UTILITY OF POSITRON EMISSION TOMOGRAPHY (PET)
Byung-Kyu Cho (*Korea*)

●Lunchtime Symposium

Sponsored by American Family Life Assurance Company of Columbus and
Specified Nonprofit Corporation Gold Ribbon Network

Chairpersons: Jong-Hyun Kim (*Korea*)
Michael Vogelbaum (*USA*)

- 12:00 **Lsy08** COST EFFECTIVENESS OF BRAIN TUMOR THERAPY
Clifford Schold (*USA*)
- 12:20 **Lsy09** HEALTH CARE AND SOCIO-MEDICAL SUPPORT SERVICES DIRECTED TO PEDIATRIC BRAIN TUMOURS PATIENTS AND THEIR FAMILIES IN CANADA.
Eric Bouffet (*Canada*)
- 12:40 **Lsy10** PSYCHOSOCIAL SUPPORT FOR CHILDREN AND ADOLESCENTS WITH BRAIN TUMORS IN
Irene Slavic (*Austria*)

●Lectures Open to the Public

Sponsored by American Family Life Assurance Company of Columbus and
Specified Nonprofit Corporation Gold Ribbon Network

Chairperson: Yukitaka Ushio (*Japan*)

- 14:00 **O048** LATE EFFECTS OF TREATMENT FOR PEDIATRIC BRAIN TUMOR PATIENTS
Stephen Sands (*USA*)
- 14:30 **O049** CARING FOR THE CAREGIVER OF A BRAIN TUMOR PATIENT
Elana Farace (*USA*)

- 15:00 **O050** LATE ENDOCRINE EFFECTS IN CHILDHOOD BRAIN TUMORS
Susumu Yokoya (*Japan*)

Break

Chairperson: Masao Matsutani (*Japan*)

- 15:40 **O051** PEDIATRIC BRAIN TUMOR: CURRENT STATUS OF PATIENT'S CARE AND A PROBLEMS IN JAPAN
Yutaka Sawamura (*Japan*)
- 16:25 **O052** COMMENTARY
Mark Kieran (*USA*)
- 16:35 **O053** ADULT BRAIN TUMORS
Jun A. Takahashi (*Japan*)
- 17:20 **O054** Commentary
W.K. Alfred Yung (*USA*)

Break

Chairpersons: Akiko Higuchi (*Japan*)
Mike Traynor (*USA*)

- 17:40 **O055** PEDIATRIC BRAIN TUMORS - FROM RESEARCH TO HOPE
Mike Traynor (*USA*)
- 17:50 **O056** THE EUROPEAN BRAIN TUMOUR PATIENT AND CAREGIVER COMMUNITY - ACHIEVEMENTS, CHALLENGES AND THE PURSUIT OF HOPE
Denis Strangman (*Australia*)
- 18:00 **O057** THE REALITY OF BRAIN TUMOURS: CURRENT STATUS AND FUTURE PERSPECTIVE IN ASIAN COUNTRIES
Akiko Higuchi (*Japan*)

May 12 (Tue) Lounge

●Hands-On Seminar: Skull Base Technique

Chairperson: Kazuhiko Mishima (*Japan*)

- 11:00 **LSe03** ANTERIOR PETROSAL APPROACH
Nobutaka Kawahara (*Japan*)
- 11:25 **LSe04** POSTERIOR PETROSAL APPROACH
Mitsuhiro Hasegawa (*Japan*)

May 13 (Wed) Room 1

●Hoshino Award Selection

Chairperson: Motoo Nagane (*Japan*)

Panel of Judges:

Mitchel Burger (*USA*) , Susan Chang (*USA*), Victor Levin (*USA*)
Erwin van Meir (*USA*), Michael Vogelbaum (*USA*)

Martin van den Bent (*Netherlands*), Rolf Bjerkvig (*Norway*)
Irene Slavic (*Austria*), Michael Weller (*Switzerland*)
Wolfgang Wick (*Germany*)

Kaya Aksoy (*Turkey*), Kyung Gi Cho (*Korea*), Yuanli Zhao (*China*)
Masao Matsutani (*Japan*), Hideyuki Saya (*Japan*)

- 08:00 **P041** ENDOTHELIAL CELL TRANSDIFFERENTIATION OF HUMAN GLIOMA STEM/ PROGENITOR CELLS IN VITRO
Yaodong Zhao (*China*)
- 08:03 **P042** THE NEW DIAGNOSIS AND TREATMENT OF PITUITARY APOPLEXY
Shou Xuefei (*China*)
- 08:06 **P043** THE MIR-17/92 POLYCISTRON IS AMPLIFIED AND UP-REGULATED IN SONIC HEDGEHOG-DRIVEN MEDULLOBLASTOMAS AND INDUCED BY N-MYC IN SONIC HEDGEHOG-TREATED CEREBELLAR NEURAL PRECURSORS
Paul A. Northcott (*Canada*)

- 08:09 **P044** MULTIPLE RECURRENT GENETIC EVENTS CONVERGE ON CONTROL OF HISTONE LYSINE METHYLATION IN MEDULLOBLASTOMA
Paul A. Northcott (*Canada*)
- 08:12 **P045** MEDIP-CHIP AND MEDIP-SEQ IDENTIFY NOVEL EPENDYMOMA TUMOUR SUPPRESSOR GENES THROUGH DELINEATION OF THE EPENDYMOMA EPIMETHYLOGENOME
Stephen Mack (*Canada*)
- 08:15 **P046** CLINICAL DIAGNOSIS OF OPTIC NERVE HEMANGIOBLASTOMA
Xuhui Bao (*China*)
- 08:18 **P047** GENE EXPRESSION META-ANALYSIS IDENTIFIES GRADING AND SURVIVAL MARKERS IN ANAPLASTIC GLIOMA
Marie de Teyrac (*France*)
- 08:21 **P048** MULTIPARAMETERIC MR APPROACH FOR TISSUE CHARACTERIZATION OF PATIENTS WITH GBM
Moran Artzi (*Israel*)
- 08:24 **P049** NG2 EXPRESSION ESTABLISHES A LINK BETWEEN NEURAL PRECURSORS AND CANCER STEM CELLS IN GLIOBLASTOMA
Talal M. Fael Al-Mayhami (*UK*)
- 08:27 **P050** UNUSUAL CASE OF RADIATION-INDUCED GROWING TERATOMA SYNDROME
Aliasgar Moiyadi (*India*)
- 08:30 **P051** CAUSES AND CORRELATES OF DISTRESS AND MAJOR DEPRESSION IN HIGH-GRADE GLIOMA
Alasdair G. Rooney (*UK*)
- 08:33 **P052** BEVACIZUMAB PLUS ERLOTINIB IN RECURRENT HIGH-GRADE GLIOMA: A PHASE II TRIAL
Sith Sathornsumetee (*USA*)
- 08:36 **P053** PATIENT FUNCTIONAL STATUS IS STRONGEST CORRELATE OF CHALLENGING BEHAVIOUR AFTER BRAIN TUMOUR
Eng-Siew Koh (*Australia*)
- 08:39 **P054** DETAILED PROSPECTIVE NEUROPSYCHOLOGICAL, ACTIVITY OF DAILY LIVING AND ENDOCRINE FUNCTION ASSESSMENT IN CHILDREN WITH CRANIOPHARYNGIOMA TREATED WITH STEREOTACTIC CONFORMAL RADIOTHERAPY
Debnarayan Dutta (*India*)
- 08:42 **P055** HUMAN NEURAL STEM CELLS CAN TARGET AND DELIVER THERAPEUTIC GENES TO BREAST CANCER BRAIN METASTASES
Kyeung Min Joo (*Korea*)
- 08:45 **P056** STEROID REQUIREMENTS DURING RADIOTHERAPY FOR MALIGNANT GLIOMAS
Athina Marantidou (*France*)
- 08:48 **P057** MUTATIONAL PROFILING OF HIGH GRADE GLIOMAS REVEALS INACTIVATING MUTATIONS IN IDH1
Fonnet E Bleeker (*Netherlands*)
- 08:51 **P058** GENOMIC PROFILING OF INTRACRANIAL GERM CELL TUMORS WITH SINGLE NUCLEOTIDE POLYMORPHISM ARRAY
Keita Terashima (*USA*)
- 08:54 **P059** PRESENCE OF AN ALTERNATIVE LENGTHENING OF TELOMERE (ALT) MECHANISM AS A FAVORABLE PROGNOSTIC MARKER IN PATIENTS WITH GLIOBLASTOMA
Kerrie L McDonald (*Australia*)
- 08:57 **P060** LONG TERM FOLLOW UP OF PATIENT WITH ACROMEGALY AFTER LINAC RADIOSURGERY
Jiun-lin Yan (*Taiwan*)
- 09:00 **P061** DO MEDULLOBLASTOMAS IN ADOLESCENTS HAVE A DISTINCT MOLECULAR SIGNATURE & DIFFERENT TUMOR BIOLOGY?
Wan-Yee Teo (*USA*)
- 09:03 **P062** ABERRANT EXPRESSION OF GDF-15 CONTRIBUTES TO PROLIFERATION AND IMMUNE ESCAPE OF MALIGNANT GLIOMAS
Patrick Roth (*Swiss*)
- 09:06 **P063** PERSONALIZED CHEMOTHERAPY BASED ON O6-METHYLGUANINE-DNAMETHYLTRANSFERASE (MGMT) EXPRESSION PATTERN FOR GLIOMA PATIENTS: EXPERIENCE OF 57 CASES
Junping Zhang (*China*)
- 09:09 **P064** CDK4/6 SMALL MOLECULE INHIBITOR PD-0332991 DEMONSTRATES ANTI-TUMOR ACTIVITY AGAINST AN INTRACRANIAL GLIOBLASTOMA XENOGRAFT LACKING p16 FUNCTION
Karine Michaud (*USA*)

- 09:12 **P065** PATIENT-SPECIFIC VIRTUAL CONTROLS CAN BE USED TO SIMULATE AND PREDICT RESPONSE TO RADIATION THERAPY IN INDIVIDUAL GLIOBLASTOMA PATIENTS
Kristin R. Swanson (*USA*)
- 09:15 **P066** AUTOPHAGY INDUCED BY VALPROIC ACID IS ASSOCIATED WITH OXIDATIVE STRESS IN GLIOMA CELL LINES
Jun Fu (*China*)
- 09:18 **P067** MANAGEMENT OF PITUITARY ADENOMA WITH STEREOTACTIC RADIOTHERAPY AT PRINCESS MARGARET HOSPITAL.
Nikhilesh Patil (*Canada*)

●Basic Science I, Genome - Proteome

Chairpersons: Zhong-ping Chen (*China*)
Koichi Ichimura (*UK*)
Do-Hyun Nam (*Korea*)

- 09:25 **P068** GENOMEWIDE ANALYSIS OF LOSS OF HETEROZYGOSITY IN GLIOBLASTOMA USING THE SNP MAPPING ARRAY AND THE PCR WITH MULTIPLE MICROSATELLITE MARKERS
Masahiro Mizoguchi (*Japan*)
- 09:28 **P069** MOLECULAR ALLELOKARYOTYPING OF MALIGNANT GLIOMA BY HIGH-RESOLUTION SINGLE NUCLEOTIDE POLYMORPHISM (SNP) OLIGONUCLEOTIDE GENOMIC MICROARRAY
Hideo Nakamura (*Japan*)
- 09:31 **P070** AN ANOCEF GENOMIC AND TRANSCRIPTOMIC MICROARRAY STUDY OF THE RESPONSE TO RADIOTHERAPY OR TO ALKYLATING FIRST-LINE CHEMOTHERAPY IN GLIOBLASTOMA PATIENTS.
Francois Ducray (*France*)
- 09:34 **P071** SELECTIVE EXPRESSION OF A SUBSET OF NEURONAL GENES IN OLIGODENDROGLIOMAWITH CHROMOSOME 1P LOSS
Akitake Mukasa (*Japan*)
- 09:37 **P072** LOSS OF HETEROZYGOSITY AT 1P-19Q INDUCES A GLOBAL CHANGE IN OLIGODENDROGLIAL TUMOR GENE EXPRESSION.
Horacio Martinetto (*Argentina*)
- 09:40 **P073** FUNCTIONAL ANALYSIS OF THE PROTEOME RELATED TO THE CHEMOTHERAPY SENSITIVITY IN ANAPLASTIC OLIGODENDROGLIOMA AND ANAPLASTIC OLIGOASTROCYTOMA
Nobuyuki Tsubota (*Japan*)
- 09:43 **P074** ESTABLISH THE OVERALL PROTEINS REFERENCE DATABASE OF HUMAN NORMAL PITUITARY USING 2D-HPLC COMBINED WITH LTQ-ORBITRAP MS
Rong Xie (*China*)
- 09:46 **P075** CD52 PROTEIN MAY BE A POTENTIAL TUMOR MARKER OF HEMANGIOBLASTOMA IN CENTRAL NERVAL SYSTEM WITH CDNA MICROARRAY FILTRATION OF THE GENE EXPRESSION PROFILES
Xing-hua Ding (*China*)
- 09:49 **P076** GENOME-WIDE ANALYSIS OF GENE EXPRESSION DURING BRAIN METASTASIS FORMATION
Norihiro Saito (*Japan*)
- 09:55 **O058** MOLECULAR GENETIC SIGNATURES THAT DEFINES SUBTYPES OF HUMAN GLIOMAS
Koichi Ichimura (*UK*)
- 10:15 **O059** INTEGRATION OF GENOMIC ALTERATIONS AND EXPRESSION PROFILING IN GLIOBLASTOMA MULTIFORME
Jean Mosser (*France*)
- 10:25 **O060** GENOME-WIDE ASSOCIATION STUDY OF ADULT GLIOBLASTOMA RISK
Jeffrey S. Chang (*USA*)
- 10:35 **O061** GENETIC DIVERSITY ASSOCIATED WITH SURVIVAL IN MALIGNANT GLIOMAS IDENTIFIED BY LINKAGE DISEQUILIBRIUM-BASED ANALYSIS OF HAPLOTYPE BLOCK REGIONS OF DNA REPAIR GENES
Francis Ali-Osman (*USA*)
- 10:45 **O062** DIFFERENTIAL GENE-EXPRESSION IN RECURRENT GLIOBLASTOMA MULTIFORME
Dietmar Krex (*Germany*)

●Lecture from SNO

Chairperson: Susan Chang (*USA*)

- 11:00 **KN03** COMPREHENSIVE GENOMIC CHARACTERIZATION OF GLIOBLASTOMA: THE CANCER GENOME ATLAS EFFORT.
Webster Cavenee (*USA*)

●Lunchtime Seminar: New Horizons: Implants Medication for Malignant Glioma Operation

Sponsored by Eisai Co., Ltd.

Chairperson: Kazuhiko Sugiyama (*Japan*)

12:00 **LSe05** EXPERIENCES WITH LOCOREGIONAL CHEMOTHERAPY FOR GLIOBLASTOMA DURING RESECTION
Manfred Westphal (*Germany*)

●Lecture from EANO

Chairperson: Michael Weller (*Switzerland*)

13:00 **KN04** THE FUTURE TREATMENT OF ANAPLASTIC GLIOMA: LESSONS FROM NOA-04 AND BEYOND
Wolfgang Wick (*Germany*)

●Ongoing Clinical Trials and the Future Direction of Glioma Treatment

Chairpersons: Ryo Nishikawa (*Japan*)
Martin van den Bent (*Netherlands*)
W.K. Alfred Yung (*USA*)

14:00 **O063** MULTI-ARM COMBINATORIAL STUDY OF SIGNAL TRANSDUCTION MODULATORS USING A SEQUENTIAL ACCRUAL DESIGN – A REPORT OF NABTC 0502
Mark Gilbert (*USA*)

14:25 **O064** PROGRESSION-FREE SURVIVAL: AN IMPORTANT ENDPOINT IN NEURO-ONCOLOGY CLINICAL TRIALS
Michael Prados (*USA*)

14:50 **O065** MULTICENTER PHASE II TRIAL OF TALAMPANEL WITH STANDARD RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: REPORT OF TWO YEAR SURVIVAL DATA
Stuart A. Grossman (*USA*)

15:15 **O066** ONGOING CLINICAL TRIALS AND THE FUTURE DIRECTION OF GLIOMA TREATMENT
Wolfgang Wick (*Germany*)

15:40 **O067** THE RESULT OF A CLINICAL TRIAL FOR MALIGNANT GLIOMAS BY JCOG-BRAIN TUMOR STUDY GROUP (JCOG 0305)
Soichiro Shibui (*Japan*)

16:05 **O068** CURRENT CLINICAL TRIALS OF GLIOMA THERAPY AND SITUATIONS OF NEUROONCOLOGY PRACTICE IN KOREA
Yong-Kil Hong (*Korea*)

●Special Lecture

Sponsored by Chugai Pharmaceutical Co.,Ltd.

Chairperson: Webster Cavenee (*USA*)

16:40 **IL04** Brain Tumor Stem Cells: New Insights and Challenges in Human and Mouse Models
Peter Dirks (*Canada*)

●Stem Cell Science Posters

Chairperson: Masamichi Takahashi (*Japan*)

17:50 **P077** HYPOXIA PROMOTES EXPANSION OF THE CD133-POSITIVE GLIOMA STEM CELLS THROUGH ACTIVATION OF HIF-1 α
Akio Soeda (*USA*)

17:53 **P078** EFFECTS OF HYPOXIA ON EXPRESSION OF A PANEL OF STEM CELL AND CHEMOSENSITIVITY MARKERS IN GLIOBLASTOMA CELL LINE-DERIVED SPHEROIDS
Jesper Kolenda (*Denmark*)

17:56 **P079** CELL MOTILITY FEATURES ARE IDENTIFIED IN THE CD133-POSITIVE GLIOMA AND ENDOTHELIAL PROGENITOR CELLS
Ping-Pin Zheng (*Netherlands*)

17:59 **P080** GLIOBLASTOMA TUMOUR INITIATING CELLS DEMONSTRATE VEGF BUT NOT PDGF AUTOCRINE SIGNALLING
Cancelled

18:02 **P081** ESTABLISHMENT OF ARTIFICIAL GLIOBLASTOMA INITIATING CELLS IN MOUSE
Takuichiro Hide (*Japan*)

18:05 **P082** CD133 ON STEM CELLS IS REQUIRED FOR APOPTOTIC INDUCTION IN GLIOMAS
Jasti S. Rao (*USA*)

18:08 **P083** TUMOR STEM-LIKE ASSOCIATED ANTIGENS AND THEIR IRRADIATIONS IMPROVE THE EFFECT OF DENDRITIC CELL-BASED VACCINATION AGAINST HUMAN GLIOMA
Wei Hua (*China*)

- 18:11 **P084** IMMUNOSUPPRESSIVE B7-H1 PROTEIN IS EXPRESSED BY DIFFERENTIATED GLIOMA CELLS BUT NOT GLIOMA STEM CELLS
Ian F. Parney (*USA*)
- 18:14 **P085** B7-H1 IS CORRELATED WITH THE MALIGNANCY GRADE OF HUMAN ASTROCYTIC TUMORS BUT IT IS NOT THE PRIVILEGE OF BRAIN TUMOR STEM-LIKE CELLS
Yu Yao (*China*)
- 18:17 **P086** EXPRESSION LEVEL OF STEM CELL MARKERS IS ASSOCIATED WITH THE SOURCE OF NEUROSPHERE MEDIA USED FOR GLIOBLASTOMA STEM CELL CULTURE.
Tony Avril (*France*)
- 18:20 **P087** AN EVALUATION OF THE NEURAL STEM CELL MARKER NG2 AS A BIOMARKER OF DISEASE IN PATIENTS WITH GLIOBLASTOMA
Colin Watts (*UK*)
- 18:23 **P088** GENE THERAPY USING TRAIL-SECRETING HUMAN UMBILICAL CORD BLOOD-DERIVED MESENCHYMAL STEM CELLS AGAINST INTRACRANIAL GLIOMA
Sin-Soo Jeun (*Korea*)

●Hoshino Award Ceremony

18:30

May 13 (Wed) Room 2

●Diagnostic Radiology

Chairperson: Hiroyuki Momota (*Japan*)

- 08:00 **P089** BRAIN EASY ANALYSIS TOOL FOR 201TL SPECT IN BRAIN TUMORS
Yasushi Shibata (*Japan*)
- 08:03 **P090** 123I-IMP SPECT IN BRAIN TUMOR: ANATOMICAL STANDARDIZED STATISTICAL MAPPING
Yasushi Shibata (*Japan*)
- 08:06 **P091** THE APPLICATION OF SUSCEPTIBILITY WEIGHTED MAGNETIC RESONANCE IMAGING (SWI) TO DIAGNOSIS AND TREATMENT OF MENINGIOMAS.
Kanji Mori (*Japan*)
- 08:09 **P092** CHOLINE-ENHANCED PROTON MRS OF BRAIN TUMORS
Mikhail Chernov (*Japan*)
- 08:12 **P093** PREOPERATIVE EVALUATION BY PROTON MAGNETIC RESONANCE SPECTROSCOPY IN THE GRADING OF GLIOMAS
Shinya Oshiro (*Japan*)
- 08:15 **P094** MODIFIED 11C-METHIONINE PET IMAGING TO DISTINGUISH RADIATION NECROSIS FROM RECURRENT GLIOMA
Shunsuke Takenaka (*Japan*)
- 08:18 **P095** MATCHING ANALYSIS OF PET AND CHEMICAL SHIFT IMAGING ON PROTON MRS IN PATIENTS WITH SUPRATENTORIAL GLIOMA
Hirohito Yano (*Japan*)
- 08:21 **P096** AUGMENTING INTRAOPERATIVE MRI WITH PREOPERATIVE DTI AND FMRI BY SIMULATION OF BRAIN DEFORMATION USING MATHEMATICAL MODEL BASED ON THIN-PLATE SPLINES:A PRELIMINARY RESEARCH
Cheng-Jun Yao (*China*)
- 08:24 **P097** THE VALUE OF RCBV RATIO IN PERFUSION MR FOR DIFFERENTIATING RADIATION NECROSIS FROM TUMOR RECURRENCE IN HIGH GRADE GLIOMA; COMPARISON WITH 18F-FDG AND 11C-METHIONINE PET
Yong Hwy Kim (*Korea*)
- 08:27 **P098** EVALUATION OF GLIOMA GRADING ON MR IMAGING: DIAGNOSTIC VALUE OF MINIMUM APPARENT DIFFUSION COEFFICIENT COMPARED WITH POSITRON-EMISSION TOMOGRAPHY
Yoshitaka Asano (*Japan*)
- 08:30 **P099** GLIOBLASTOMA TREATED WITH POSTOPERATIVE RADIO-CHEMOTHERAPY: PROGNOSTIC VALUE OF APPARENT DIFFUSION COEFFICIENT AT MR IMAGING
Fumiyuki Yamasaki (*Japan*)
- 08:33 **P100** DIFFUSION-WEIGHTED IMAGING IN PATIENTS WITH GLIOBLASTOMA MULTIFORME TREATED WITH BEVACIZUMAB
Kevin P. Becker (*USA*)

08:36 **P101** EVALUATION OF ANTI-ANGIOGENIC THERAPY RESPONSE IN PATIENTS WITH GBM; A HOMODYNAMIC RESPONSE IMAGING STUDY
Dafna Ben Bashat (*Israel*)

08:39 **P102** PROGNOSTIC SIGNIFICANCE OF GROWTH KINETICS IN NEWLY DIAGNOSED GLIOBLASTOMA: A ROLE FOR PATIENT-SPECIFIC VIRTUAL CONTROLS
Kristin R. Swanson (*USA*)

Chairpersons: Takanori Ohnishi (*Japan*)
Robert Grant (*Scotland*)

Keynote

08:50 **KN05** MR METABOLIC AND PHYSIOLOGICAL IMAGING OF PATIENTS WITH GLIOMA
Sarah Nelson (*USA*)

09:20 **O069** HISTOGRAM ANALYSIS OF PERFUSION MR IMAGING DATA FOR THE ASSESSMENT OF TUMOR RESPONSE DURING GLIOMA THERAPY
Se-Hyuk Kim (*Korea*)

09:30 **O070** DYNAMIC PERFUSION MR IMAGES CAN PREDICT THE PSEUDOPROGRESSION MIMICKING TRUE PROGRESSION IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA
Doo-Sik Kong (*Korea*)

●Novel Treatment Approach

Chairpersons: Takamitsu Fujimaki (*Japan*)
Xuejun Yang (*China*)

10:30 **P103** EFFECTIVENESS OF GOREI-SAN (WULING SAN) FOR ELIMINATING BRAIN EDEMA DUE TO MALIGNANT BRAIN TUMORS
Akimune Hayashi (*Japan*)

10:33 **P104** IMAGE GUIDED CONVECTION-ENHANCED DELIVERY OF NIMUSTINE HYDROCHLORIDE (ACNU) IN RECURRENT GLIOMA PATIENTS
Ryuta Saito (*Japan*)

10:36 **P105** CONVECTION ENHANCED DELIVERY OF NIMUSTINE HYDROCHLORIDE (ACNU) WITH SYSTEMIC ADMINISTRATION OF TEMOZOLOMIDE IN RECURRENT GLIOMA PATIENTS
Yukihiko Sonoda (*Japan*)

10:40 **O071** THE ANTI-TUMOR EFFECT OF CONVECTION-ENHANCED DELIVERY OF MICELLE-AM80 WITH SYSTEMIC ADMINISTRATION OF TEMOZOLOMIDE.
Michiko Yokosawa (*Japan*)

10:50 **O072** AN IMPLANTABLE MAGNETIC BREATHING PUMP FOR METRONOMIC CONVECTION ENHANCED DELIVERY OF BIOLOGICAL AGENTS IN MALIGNANT GLIOMAS
Thomas C. Chen (*USA*)

11:00 **O073** INTRACEREBRAL ADMINISTRATION OF CPG OLIGONUCLEOTIDE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA.A PHASE II STUDY.
Renata Ursu (*France*)

11:10 **O074** BIODISTRIBUTION AND IMAGING STUDIES ON TRANSFERRIN TARGETING PEG LIPOSOME ENCAPSULATING BOTH BSH AND IODINE CONTRAST AGENT BY CONVECTION ENHANCED DELIVERY ON RAT GLIOMA FOR EXPERIMENTAL BORON NEUTRON CAPTURE THERAPY
Shiro Miyata (*Japan*)

11:20 **O075** INTRAOPERATIVE PHOTODYNAMIC DIAGNOSIS AND THERAPY FOR MALIGNANT GLIOMA USING SECOND-GENERATION PHOTSENSITIZER TALAPORFIN SODIUM
Jiro Akimoto (*Japan*)

●Lunchtime Seminar

Sponsored by Daiichi-Sankyo Co., Ltd.

Chairperson: Ryo Nishikawa (*Japan*)

12:00 **LSe06** MOLECULARLY TARGETED THERAPIES FOR GLIOBLASTOMA: NEW APPROACHES FOR PERSONALIZED MEDICINE
Paul Mischel (*USA*)

●Basic Science II

Chairpersons: Shiyuan Cheng (USA)
Beatrice Malmer (Sweden)
Motoo Nagane (Japan)

Keynote

- 13:00 **KN06** BRAIN TUMOR INITIATION AND DEVELOPMENT, INFLUENCE OF CANCER STEM-LIKE CELLS.
Rolf Bjerkvig (Norway)
- 13:30 **O076** MUTATIONAL PROFILING OF HIGH GRADE GLIOMAS REVEALS INACTIVATING MUTATIONS IN IDH1
Fonnet E Bleeker (Netherlands)
- 13:50 **O077** KCN1, A NOVEL SMALL MOLECULE HIF INHIBITOR PREVENTS GLIOMA GROWTH THROUGH BINDING OF PLECTIN-1 AND INHIBITION OF THE HSP90 PATHWAY
Erwin G Van Meir (USA)
- 14:10 **O078** DIRECT TYROSINE PHOSPHORYLATION OF GSTP1 BY EGFR INDUCES JNK ACTIVATION IN GLIOBLASTOMA CELLS
Tatsunori Okamura (USA)
- 14:20 **O079** QUANTITATIVE EXPRESSION ANALYSIS REVEALED SIGNIFICANT CORRELATION OF EGFR VARIANT III (VIII) AND NOTCH EXPRESSION IN GLIOBLASTOMA
Koji Yoshimoto (Japan)
- 14:40 **O080** EGFRvIII PREFERENTIALLY ACTIVATES STAT5 AND GAB1, CAN BE ACTIVATED BY FORCED DIMERIZATION AND LOCATES TO THE NUCLEUS
Oliver Bogler (USA)
- 14:50 **O081** ASSOCIATION OF POLYMORPHIC VARIANTS IN EGFR AND LRIG2 AND MENINGIOMA RISK
Soma Ghasimi (Sweden)

Break

Chairpersons: Rolf Bjerkvig (Norway)
Oliver Bogler (USA)
Erwin G. Van Meir (USA)

- 15:30 **O082** A NOVEL P53 BYSTANDER EFFECT: PARACRINE INDUCTION OF APOPTOSIS IN TUMOR CELLS THROUGH THE INDUCTION OF GALECTIN-3 SECRETION
Erwin G. Van Meir (USA)
- 15:40 **O083** P53: AN ANTAGONIST OF EGFR-MEDIATED METABOLIC ACTIVITY IN HUMAN MALIGNANT GLIOMA CELLS
Joachim Steinbach (Germany)
- 15:50 **O084** SPONTANEOUS TRANSFORMATION OF p53 NULL SUBVENTRICULAR ZONE CELLS IN VIVO, AND USE IN ORTHOTOPIC THERAPEUTIC TESTING
Rintaro Hashizume (USA)
- 16:00 **O085** ADP-RIBOSYLATION FACTOR 6 REGULATES GLIOMA CELL INVASION THROUGH THE IQ-DOMAIN GTPASE-ACTIVATING PROTEIN 1-RAC1-MEDIATED PATHWAY
Shi-Yuan Cheng (USA)
- 16:20 **O086** ROLES OF SPHINGOSINE-1-PHOSPHATE RECEPTOR IN GLIOMA CELL PROLIFERATION AND PATIENTS SURVIVAL
Mitsutoshi Nakada (Japan)
- 16:30 **O087** EPHA3 REGULATES CANCER PROGENITOR CELL SELF-RENEWAL AND PROLIFERATION IN GLIOMA NEUROSPHERE CULTURES
Bryan W. Day (Australia)
- 16:40 **O088** THE ALTERNATIVE TRKAIII SPLICE VARIANT, EXPRESSED BY NEUROBLASTOMAS AND GLIOBLASTOMAS, TARGETS THE CENTROSOME AND PROMOTES GENETIC INSTABILITY
Cancelled
- 16:50 **O089** PRESENCE OF AN ALTERNATIVE LENGTHENING OF TELOMERE (ALT) MECHANISM AS A FAVORABLE PROGNOSTIC MARKER IN PATIENTS WITH GLIOBLASTOMA
Kerrie L. McDonald (Australia)
- 17:10 **O090** PROGNOSTIC SIGNIFICANCE OF MICRORNA-196 IN GLIOBLASTOMA
Yanlei Guan (Japan)
- 17:20 **O091** DEVELOPMENT OF A NOVEL MOUSE MODEL OF GLIOBLASTOMA MULTIFORME USING LENTIVIRAL VECTORS
Tomotoshi Marumoto (Japan)
- 17:30 **O092** PHENOTYPIC MODULATION OF EXPERIMENTAL GLIOMAS: PROGRESSION FROM GLIOMATOSIS CEREBRI-LIKE LESIONS TO GLIOBLASTOMA
Jian Wang (Norway)

- 17:40 **O093** ISOLATION AND CHARACTERIZATION OF INTERLEUKIN 13 RECEPTOR ALPHA2-SPECIFIC HEPTAPEPTIDES
Waldemar Debinski (*USA*)
- 17:50 **O094** AUTOLOGOUS SH3-DOMAIN GRB2-LIKE 1 (SH3GL1) ANTIBODY AS A NOVEL SERUM MARKER SPECIFIC TO LOW-GRADE GLIOMA
Tomoo Matsutani (*Japan*)
- 18:00 **O095** HIGH SOLUBLE P-SELECTIN AND LOW PLATELET COUNT AS THROMBOSIS RISK MARKERS IN GLIOMA PATIENTS
Rainer Vormittag (*Austria*)

May 13 (Wed) Room 3

●Glioma

Chairpersons: Yong-Kil Hong (*Korea*)
Jun A. Takahashi (*Japan*)

- 08:00 **P106** SURVIVAL OF PATIENTS WITH GLIOBLASTOMA MULTIFORME AT HARTFORD HOSPITAL
Alexandra Flowers (*USA*)
- 08:03 **P107** SINGLE CENTER SURVIVAL OUTCOMES OF 167 GLIOBLASTOMA PATIENTS: BEFORE AND AFTER TEMOZOLOMIDE
Ufuk Abacioglu (*Turkey*)
- 08:06 **P108** CLINICAL OUTCOMES OF ADULT SUPRATENTORIAL GRADE 3 MALIGNANT GLIOMAS IN A SINGLE INSTITUTION
Yoshitaka Narita (*Japan*)
- 08:09 **P109** GLUCOCORTICOID-INDUCED BONE FRACTURE IN PROGRESSIVE GLIOMA PATIENTS
Aya Shinomiya (*Japan*)
- 08:12 **P110** NEWLY DIAGNOSED PREGNANCY AND GLIOBLASTOMA MULTIFORME (GBM): AN ETHICAL COLLISION COURSE
Glen H.J. Stevens (*USA*)
- 08:15 **P111** VNTRICULAR AND LEPTOMENINGEAL SEEDING IN A PATIENT WITH MEDULLARY ANAPLASTIC OLIGODENDROGLIOMA
Young-Cho Koh (*Korea*)
- 08:18 **P112** LONG-TERM OUTCOME OF LOW-GRADE GLIOMAS TREATED WITH RADIOTHERAPY-DEFERRING THERAPEUTIC POLICY
Yasuo Iwadate (*Japan*)
- 08:21 **P113** CONSIDERATIONS FOR DIAGNOSIS AND TREATMENT OF CLASSICAL GLIOMATOSIS CEREBRI
Kazuya Aoki (*Japan*)
- 08:25 **O096** CLINICAL OUTCOME AND PROGNOSTIC FACTORS OF GLIOMATOSIS CEREBRI
Jeong Hoon Kim (*Korea*)
- 08:35 **O097** CASE-CONTROL STUDY OF LONG TERM SURVIVORS OF PRIMARY GLIOBLASTOMA
Eudocia C. Quant (*USA*)
- 08:45 **O098** EFFECTS OF PREGNANCY ON NATURAL HISTORY OF WHO GRADE II GLIOMAS. A QUANTITATIVE ANALYSIS OF THE TUMOR GROWTH RATES.
Luc Taillandier (*France*)

●Metastatic Brain Tumors

Chairpersons: Akio Asai (*Japan*)
Yong Gu Chung (*Korea*)

- 09:10 **P114** GROWTH RATES OF METASTATIC BRAIN TUMORS IN NON-SMALL CELL LUNG CANCER; ESTIMATION FROM MICRO-METASTASIS
Heon Yoo (*Korea*)
- 09:13 **P115** PROGNOSTIC FACTORS IN 57 PATIENTS WITH METASTATIC BRAIN TUMORS FROM BREAST CANCER.
Tomohiko Ozaki (*Japan*)
- 09:16 **P116** INTRAMEDULLARY SPINAL CORD METASTASIS IN BREAST CARCINOMA, CASE REPORT.
Lumir Hrabalek (*Czech*)
- 09:19 **P117** SPINAL CORD METASTASIS OF ADENOCARCINOMA, CASE REPORT
Ondrej Kalita (*Czech*)

- 09:22 **P118** COMPLETE RESPONSE OF A LARGE RECURRENT METASTATIC BRAIN TUMOR TREATED BY CYBERKNIFE: A CASE REPORT AND REVIEW OF LITERATURE
Da-Tong Ju (*Taiwan*)
- 09:25 **P119** CONTINUOUS INTRATHECAL TREATMENT WITH METHOTREXATE VIA "VENTRICULAR PORT" FOR LEPTOMENINGEAL DISSEMINATION OF MALIGNANT TUMORS
Yusuke Tabei (*Japan*)
- 09:30 **O099** WHOLE-BRAIN RADIOTHERAPY VERSUS OBSERVATION AFTER RADIOSURGERY OR SURGERY OF 1-3 BRAIN METASTASES - RESULTS OF THE EORTC 22952-26001 PHASE III STUDY
Riccardo Soffietti (*Italia*)
- 09:50 **O100** THE IMPACT OF CYST FORMATION AND TUMOR HEMORRHAGE ON LOCAL RECURRENCE IN BRAIN METASTASIS
Heon Yoo (*Korea*)
- 10:00 **O101** NEOPLASTIC MENINGITIS - IS MRI AS SENSITIVE AS CSF CYTOLOGY?
Peter Proemmel (*Germany*)
- 10:10 **O102** IMMUNOTHERAPY WITH CPG-ODN IN NEOPLASTIC MENINGITIS(FOR PATIENTS WITH NEOPLASTIC): PHASE I TRIAL.
Renata Ursu (*France*)

●Strategies for Management of Patients With Brain Tumors in Emerging Countries

Chairperson: Jonathan Finlay (*USA*)

Keynote

- 11:00 **KN07** CAN WE DEVELOP MANAGEMENT STRATEGIES FOR ADULTS AND CHILDREN WITH PRIMARY BRAIN TUMORS IN LOW INCOME COUNTRIES?
Jonathan Finlay (*USA*)
- 11:30 **O103** ESTABLISHING MYELOABLATIVE CHEMOTHERAPY PROTOCOLS IN LOW-RESOURCE COUNTRIES: THE PAKISTAN EXPERIENCE OF THE CURE2CHILDREN FOUNDATION.
Lawrence B. Faulkner (*Italy*)
- 11:42 **O104** MANAGEMENT OF BRAIN TUMORS IN THE PHILIPPINES
Julette-Marie F. Batarra (*Philippines*)
- 11:54 **O105** THE CHALLENGES OF BUILDING AND SUSTAINING A PEDIATRIC NEURO-ONCOLOGY PROGRAM IN A DEVELOPING COUNTRY
Ibrahim Qaddoumi (*USA*)
- 12:06 **O106** CHILDHOOD BRAIN TUMORS INCIDENCE AND CARE IN THE KYRGYZ REPUBLIC
Emil Makimbetov (*Kyrgyzstan*)
- 12:18 **O107** MANAGEMENT OF CANCER PAIN IN DEVELOPING COUNTRIES
Stuart A. Grossman (*USA*)
- 12:20 **O175** THE ARGENTINE PEDIATRIC ONCOLOGY REGISTRY AS A TOOL TO EVALUATE THE SITUATION OF CHILDREN WITH CNS TUMORS IN ARGENTINA.
Florencia Moreno (*Argentina*)

●Epidemiology

Chairperson: Soichiro Shibui (*Japan*)

- 13:00 **P120** POPULATION BASED EPIDEMIOLOGY OF CENTRAL NERVOUS SYSTEM (CNS) MALIGNANCIES IN THE GIRONA PROVINCE (SPAIN). RESULTS OF AN 11 YEARS SURVEY (1994-2004).
Rafel Fuentes (*Spain*)
- 13:05 **O108** DESCRIPTIVE EPIDEMIOLOGY OF CEREBRAL GLIOMAS IN ALBANIA; COMPARATIVE ANALYSIS DURING THE PERIOD OF 1993-2004
Gentian Kaloshi (*Republic of Albania*)
- 13:15 **O109** AGE AS PREDICTIVE FACTOR IN GLIOBLASTOMAS: POPULATION-BASED STUDY
Daisuke Kita (*Japan*)

●Sellar/Parasellar Lesions

Chairpersons: Kaya Aksoy (*Turkey*)
Fengping Huang (*China*)
Sun Ho Kim (*Korea*)

- 13:35 **O110** TUMOR TISSUE IDENTIFICATION IN THE PSEUDOCAPSULE OF PITUITARY ADENOMA: SHOULD THE PSEUDOCAPSULE BE REMOVED FOR TOTAL RESECTION OF PITUITARY ADENOMA?
Sun Ho Kim (*Korea*)

- 13:45 **O111** MANAGEMENT OF PITUITARY ADENOMA WITH STEREOTACTIC RADIOTHERAPY AT PRINCESS MARGARET HOSPITAL.
Nikhilesh Patil (*Canada*)
- 13:55 **O112** LONG TERM FOLLOW UP OF PATIENT WITH ACROMEGALY AFTER LINAC RADIOSURGERY
Jiun-lin Yan (*Taiwan*)
- 14:05 **O113** SEVERAL TIPS TO AVOID COMPLICATIONS OF INTRACYSTIC CHEMOTHERAPY WITH BLEOMYCIN FOR CRANIOPHARYNGIOMA IN CHILDREN
Akira Gomi (*Japan*)
- 14:15 **O114** INTRACYSTIC BLEOMYCIN THERAPY FOR CRANIOPHARYNGIOMA IN CHILDREN.
Ting-Rong Hsu (*Taiwan*)
- 14:25 **O115** INTRATUMORAL BLEOMYCIN INJECTION AS A PRIMARY THERAPY FOR CYSTIC CRANIOPHARYNGIOMA
Seung-Ho Yang (*Korea*)
- 14:35 **O116** DIFFERENTIAL IMAGING CHARACTERS OF THE TUMORS INVOLVING THE CAVERNOUS SINUS
Liang Chen (*China*)

●Meningnioma, Chordoma

Chairpersons: Sang-Won Lee (*Korea*)
Yang Weizhong (*China*)

- 14:50 **O117** RESULTS OF THE QUEEN SQUARE MENINGIOMA STUDY: EPIDEMIOLOGY, EPILEPTIC CHARACTERIZATION, PRESENTING SYMPTOMS, TREATMENT, CLINICAL OUTCOME AND RECURRENCE.
Say Ayala (*UK*)
- 15:00 **O118** Ki67 PROLIFERATION INDEX DOES NOT PREDICT SURVIVAL IN PATIENTS WITH NON-BENIGN MENINGIOMAS: ANALYSIS OF 86 CASES
Andrej Vranic (*Slovenia*)
- 15:10 **O119** ANALYSIS OF 56 MENINGIOMA CASES CLASSIFIED AS WHO GRADE III
Ye Gong (*China*)
- 15:20 **O120** CHORDOMA AND CHONDROSARCOMA OF THE SKULL BASE: COMPARATIVE ANALYSIS OF OUTCOMES IN 30 PATIENTS
Jeong Hoon Kim (*Korea*)
- 15:30 **O121** TREATMENT WITH HIGH MARGINAL DOSE IS MANDATORY TO ACHIEVE LONG-TERM CONTROL OF SKULL BASE CHORDOMAS AND CHONDROSARCOMAS BY MEANS OF STEREOTACTIC RADIOSURGERY
Tomoyuki Koga (*Japan*)
- 15:40 **O122** RESULTS OF PROTON BEAM THERAPY FOR CHORDOMA AND CHONDROSARCOMA OF THE SKULL BASE: SHIZUOKA CANCER CENTRE EXPERIENCE
Yoko Nakasu (*Japan*)

●Poster Presentations: Neurosurgery

Chairperson: Junichi Adachi (*Japan*)

- 16:00 **P121** THE FIRST FINGERPRINTS OF NEUROONCOLOGY IN PREHISTORIC ERA; PREHISTORIC TRAPENATED SKULLS MAY BE THE FIRST ATTRACT TO TREAT TUMORS IN NEUROONCOLOGY
Cengiz Cokluk (*Turkey*)
- 16:03 **P122** EXPANDED ENDONASAL RESECTION OF SUPRA- AND EXTRA-SELLAR LESIONS
Doo-Sik Kong (*Korea*)
- 16:06 **P123** EXTENDED ENDOSCOPIC ENDONASAL TRANSSPHENOIDAL APPROACH FOR SKULL BASE LESION - AVAILABILITY OF MULTILAYERED RECONSTRUCTION METHOD -
Shigetoshi Yano (*Japan*)
- 16:09 **P124** RESULTS OF EXTENDED TSA TO ANTERIOR SKULL BASE
Seong M. Kim (*Korea*)
- 16:12 **P125** TWO-SURGEONS TECHNIQUE FOR INFRATEMPORAL FOSSA TUMOR; SIMULTANEOUS LATERAL TRANSZYGOMATIC AND ENDOSCOPIC ENDONASAL APPROACHES WITH TECHNICAL NOTE
Shin Jung (*Korea*)
- 16:15 **P126** APPLICATION OF ENDOSCOPES IN MINIMALLY INVASIVE NEUROSURGERY
Chiung-Chyi Shen (*Taiwan*)
- 16:18 **P127** CLINICAL CORRELATION BETWEEN PERITUMORAL EDEMA AND VARIOUS FACTORS IN MENINGIOMA.
Jeong-Taik Kwon (*Korea*)
- 16:21 **P128** MENINGIOMA OPERATIONS IN THE ELDERLY PATIENTS: EFFICIENT WAY TO INTERNAL DECOMPRESSION
Sun-Chul Hwang (*Korea*)

- 16:24 **P129** A 57-PATIENT EXPERIENCE ON THE SURGICAL STRATEGIES OF PETROCLIVAL MENINGIOMAS
Peiliang Li (*China*)
- 16:27 **P130** RETROSPECTIVE ANALYSIS OF THE POST-OPERATIVE OUTCOME OF PETROCLIVAL MENINGIOMAS
Matthias Kirsch (*Germany*)
- 16:30 **P131** ADVANTAGES OF THE PTERIONAL APPROACH FOR OLFACTORY GROOVE AND TUBERCULUM SELLAE MENINGIOMAS
Chul-gu Jung (*Korea*)
- 16:33 **P132** MENINGIOMA ARISING FROM THE LATERAL RECESS OF 4TH VENTRICLE
Seong M. Kim (*Korea*)
- 16:36 **P133** SURGICAL MANAGEMENT FOR TRIGEMINAL SCHWANNOMA
Chao Zhang (*China*)
- 16:39 **P134** LATERAL OR ANTEROLATERAL APPROACH FOR LARGE DUMBBELL-SHAPED CERVICAL NEURINOMA
Mingguang Zhang (*China*)
- 16:42 **P135** CLINICAL COURSE OF PITUITARY ADENOMA AFTER APOPLEXY
Yong Hwuy Kim (*Korea*)
- 16:45 **P136** EFFICACY AND SAFETY OF CABERGOLINE AS A FIRST LINE TREATMENT FOR INVASIVE GIANT MALE PROLACTINOMA
Jeong Hoon Kim (*Korea*)
- 16:48 **P137** COMPARISON OF LATERAL AND SUPERIOR WALLS OF THE PITUITARY FOSSA WITH CLINICAL EMPHASIS ON PITUITARY ADENOMA EXTENTION: CADAVERIC-ANATOMIC STUDY
Kaya Aksoy (*Turkey*)
- 16:51 **P138** METASTATIC ACTH PRODUCING PITUITARY CARCINOMA (PCA) TREATED WITH TEMOZOLOMIDE(T): CASE REPORT AND REVIEW OF THE LITERATURE
Sarah Taylor (*USA*)
- 16:54 **P139** ISOLATED OCULAR PARESIS IN THE PITUITARY ADENOMA: REVIEW OF 4 CASES
Sun-Chul Hwang (*Korea*)
- 16:57 **P140** THE EFFECTIVE TREATMENT OF CRANIOPHARYNGIOMA USING HIGHLY CONFORMAL HYPOFRACTIONATED STEREOTACTIC IRRADIATION
Moon-Jun Sohn (*Korea*)
- 17:03 **P141** LYMPHOCYTIC HYPOPHYSITIS WITH REFERENCE TO MR IMAGING
Jeong-Hyun Hwang (*Korea*)
- 17:06 **P142** CENTRAL NEUROCYTOMA PRESENTING WITH INTRAVENTRICULAR HEMORRHAGE
Min-Su Kim (*Korea*)
- 17:09 **P143** CLINICAL TREATMENT OF INTRACRANIAL MALIGNANT NERVE SHEATH TUMORS
Kang Zheng (*China*)
- 17:12 **P144** A RARE TUMOR-LIKE LESION OF PERIPHERAL NERVE SHEATH IN AN UNUSUAL SITE. NEUROMUSCULAR CHORISTOMA OF INTRAORBITAL RETROBULBAR CONUS. A CASE REPORT AND LITERATURE REVIEW.
Suat Boyaci (*Turkey*)
- 17:15 **P145** CLINICAL EXPERIENCES OF INTRACRANIAL HEMANGIOBLASTOMA
Seung Heon Cha (*Korea*)
- 17:18 **P146** SURGICAL MANAGEMENT OF CNS HEMANGIOBLASTOMAS IN VON HIPPEL-LINDAU DISEASE
Hiroshi Kanno (*Japan*)
- 17:21 **P147** CLINICAL DIAGNOSIS AND TREATMENT OF HYPOTHALAMIC HAMARTOMA IN CHILDREN
Fengping Huang (*China*)
- 17:24 **P148** CLINICAL DIAGNOSIS AND TREATMENT OF THIRD VENTRICLE CAVERNOUS ANGIOMA
Gang Wu (*China*)
- 17:27 **P149** MULTIFOCAL, PROTEINACEOUS CNS DEPOSITS MIMICKING NEOPLASIA: REPORT OF AN UNUSUAL CEREBRAL AND CEREBELLAR AMYLOIDOMA WITH LONG LASTING CLINICAL HISTORY
Peter Molnar (*Hungary*)
- 17:30 **P150** PRIMARY BURKITT LYMPHOMA OF CNS IN AN IMMUNOCOMPETENT OLD WOMAN: A RARE CASE REPORT AND REVIEW LITERATURES
Jui-Ming Sun (*Taiwan*)
- 17:33 **P151** PRIMARY LEPTOMENINGEAL MELANOMATOSIS IN A 31-YEAR-OLD WOMAN
Young-Cho Koh (*Korea*)

- 17:36 **P152** PRIMARY INTRACEREBRAL MALIGNANT FIBROUS HISTIOCYTOMA, CASE REPORT
Young-Cho Koh (*Korea*)
- 17:39 **P153** INCIDENTALLY DISCOVERED CLIVAL PSEUDOMENINGOCELE : A CASE REPORT
Seong M. Kim (*Korea*)
- 17:42 **P154** MALIGNANT BRAIN TUMOR IN A PATIENT WITH AIDS
Bong Jin Park (*Korea*)
- 17:45 **P155** GLIOBLASTOMA DEVELOPED IN A CURED PEDIATRIC CNS LEUKEMIA
Bong Jin Park (*Korea*)
- 17:48 **P156** A PATIENT WITH GLIOBLASTOMA MULTIFORME AND A LEFT CERVICAL MASS- A CASE REPORT
Jarungchai Vatanagul (*Philippines*)
- 17:51 **P157** GLIOBLASTOMA MULTIFORME IN FASCIA LATA
Ahmet Kahraman (*Turkey*)
- 17:54 **P158** INTRAPARENCHYMAL GERMINOMA
Bong Jin Park (*Korea*)
- 17:57 **P159** EARLY DETECTION OF THE VENOUS THROMBOEMBOLISM IN GLIOMA PATIENT
Tomohiro Kawaguchi (*Japan*)
- 18:00 **P160** 2 CASES OF EXTRADURAL GLIOBLASTOMA MULTIFORME PRESENTING AS TRIGEMINAL NEURALGIA;
PATTERNS OF MOLECULAR TARGETS OF INVASIVENESS.
Lawrence Cher (*Australia*)
- 18:03 **P161** PONTINE CRYPTOCOCAL GRANULOMA IN A HEALTHY, NON-IMMUNOCOMPROMISED PATIENT-CASE
REPORT-
Kyung Gi Cho (*Korea*)
- 18:06 **P162** SURGERY FOR INTRAMEDULLARY SPINAL TUMORS
Guihuai Wang (*China*)
- 18:09 **P163** THE RATIONAL NEUROSURGICAL TREATMENT OF PINEAL REGION TUMORS
Chen Jin-cai (*China*)
- 18:12 **P164** CONSERVATIVE MANAGEMENT OF PSEUDOMENINGOCEAL FORMATION AFTER POSTERIOR FOSSA
TUMOR SURGERY IN CHILDREN
Sang-Dae Kim (*Korea*)
- 18:15 **P165** POSTERIOR FOSSA TUMORS WITH HYDROCEPHALUS: OUTCOME OF SURGERY WITHOUT CSF DIVERSION
Gerardo D. Legaspi (*Philippines*)
- 18:18 **P166** ATYPICAL MENINGIOMA IN FRENCH WEST INDIES
Keyvan Mostofi (*France*)
- Display only **P167** ATYPICAL RATHKE'S CLEFT CYST WITH CALCIFICATION
Lu-Ting Kuo (*Taiwan*)

May 14 (Thu) Room 1

●Temozolomide and MGMT

Chairpersons: Yuichi Hirose (*Japan*)
Tali Siegal (*Israel*)

- 08:00 **P168** THE CORRELATION AND PROGNOSTIC SIGNIFICANCE OF MGMT PROMOTER METHYLATION AND THE
MGMT PROTEIN IN GLIOBLASTOMAS
Tae-Young Jung (*Korea*)
- 08:03 **P169** RELEVANCE OF MSP ASSAY FOR THE DETECTION OF MGMT PROMOTER HYPERMETHYLATION IN
GLIOBLASTOMAS
Kazunari Yachi (*Japan*)
- 08:06 **P170** CLINICAL SIGNIFICANCE OF POLYMORPHISM OF DNA REPAIR GENE MGMT IN GLIOBLASTOMAS
Takao Fukushima (*Japan*)
- 08:09 **P171** IMMUNOHISTOCHEMICAL ASSESSMENT OF O6-METHYLGUANINE DNA METHYLTRANSFERASE FOR
GLIOBLASTOMAS: A REAPPRAISAL
Manabu Natsumeda (*Japan*)
- 08:12 **P172** MGMT METHYLATION STATUS MAY PREDICT SURVIVAL IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED
GLIOBLASTOMA (GBM)
Elizabeth R. Gerstner (*USA*)

- 08:15 **P173** METHYLATION-SENSITIVE HIGH RESOLUTION MELTING ANALYSIS :A NEW QUANTITATIVE ASSESSMENT OF MGMT PROMOTER METHYLATION IN GLIOMAS
Jun-ichi Adachi (*Japan*)
- 08:18 **P174** MGMT TESTINGS FOR TEMOZOLOMIDE EFFICACY ON GLIOBLASTOMA
Motoo Nagane (*Japan*)
- 08:21 **P175** A NOVEL AND SPECIFIC INHIBITOR OF MGMT TRANSCRIPTION INCREASES THE SENSITIVITY OF GLIOMA CELL LINES TO TEMOZOLOMIDE TREATMENT.
Iris Lavon (*Israel*)
- 08:24 **P176** MECHANISM OF THALIDOMIDE TO ENHANCE THE CYTOTOXICITY OF TEMOZOLOMIDE IN U251-MG GLIOMA CELLS IN VITRO
Xuejun Yang (*China*)
- 08:27 **P177** NEURAL DIFFERENTIATION MARKERS EXPRESSION IN HUMAN GLIOBLASTOMAS MAY PREDICT THEIR RESPONSE TO CHEMOTHERAPY
Igor J. Sulla (*Slovak*)
- 08:30 **P178** EXTENDED USE OF TEMOZOLOMIDE BASED ON O6-METHYLGUANINE-DNAMETHYLTRANSFERASE (MGMT) EXPRESSION PATTERN FOR GLIOMA PATIENTS: EXPERIENCE OF 17 CASES
Zhongping Chen (*China*)
- 08:33 **P179** PYSOSEQUENCING: A GOOD OPTION FOR MGMT ANALYSIS.
Veronique Quillien (*France*)
- 08:36 **O123** CDK INHIBITOR BLOCKS DNA REPAIR FOLLOWING G2 CHECKPOINT ACTIVATION IN HUMAN GLIOMA CELLS TREATED WITH TEMOZOLOMIDE
Yuichi Hirose (*Japan*)
- 08:46 **O124** TEMOZOLOMIDE-INDUCED DIFFERENTIAL EXPRESSION OF DNA REPAIR GENES IN MALIGNANT GLIOMA CELLS
Congju Zhu (*Singapore*)
- 09:00 **O125** MGMT PROMOTER GENE METHYLATION AS DETERMINED WITH MULTIPLEX LIGATION-DEPENDANT PROBE AMPLIFICATION (MLPA) IS PROGNOSTIC FOR SURVIVAL AFTER RADIOTHERAPY BUT NOT PREDICTIVE FOR OUTCOME TO CHEMOTHERAPY IN OLIGODENDROGLIAL TUMORS
Martin van den Bent (*Netherlands*)

●Angiogenesis and Anti-Angiogenesis Therapy

Chairpersons: Turker Kilic (*Turkey*)
Roger Stupp (*Switzerland*)
Patric Y. Wen (*USA*)

- 09:15 **P180** ANGIOGENIC POTENTIAL OF LOW GRADE OLIGODENDROGLIOMAS IS AN IMPORTANT DETERMINANT OF PROGNOSIS
Turker Kilic (*Turkey*)
- 09:18 **P181** IDENTIFICATION OF A NOVEL SMALL MOLECULE HIF-1 α TRANSLATION INHIBITOR
Takuhito Narita (*USA*)
- 09:21 **P182** PHASE I STUDY OF VANDETANIB, IMATINIB MESYLATE AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA
David A. Reardon (*USA*)
- 09:24 **P183** A PHASE I STUDY OF SUNITINIB PLUS IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMA
David A. Reardon (*USA*)
- 09:27 **P184** A PHASE IB TRIAL OF CEDIRANIB IN ADDITION TO STANDARD TEMOZOLOMIDE AND RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Andrew S. Chi (*USA*)
- 09:30 **O126** A PHASE I, OPEN LABEL, MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF CEDIRANIB [RECENTINTM] IN COMBINATION WITH LOMUSTINE CHEMOTHERAPY FOR PATIENTS WITH RECURRENT GLIOBLASTOMA
T.T. Batchelor (*USA*)
- 09:40 **O127** MULTIARM COMBINATORIAL STUDY OF SIGNAL TRANSDUCTION MODULATORS USING A SEQUENTIAL ACCRUAL DESIGN: A REPORT OF THE NORTH AMERICAN BRAIN TUMOR CONSORTIUM (NABTC) 0502
Mark R. Gilbert (*USA*)
- 10:00 **O128** PHASE II STUDY OF BEVACIZUMAB PLUS ETOPOSIDE AMONG RECURRENT MALIGNANT GLIOMA PATIENTS: FINAL STUDY RESULTS
David A. Reardon (*USA*)

- 10:10 **O129** BEVACIZUMAB AND NITROSOUREA IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA: A PHASE II MULTICENTER ITALIAN STUDY
Roberta Ruda' (*Italia*)
- 10:20 **O130** BEVACIZUMAB PLUS ERLOTINIB IN RECURRENT HIGH-GRADE GLIOMA: A PHASE II TRIAL
Sith Sathornsumetee (*USA*)
- 10:30 **O131** PHENOTYPIC AND PHYSIOLOGIC EFFECTS OF BEVACIZUMAB IN A HIGHLY INFILTRATIVE AND ANGIOGENIC HUMAN GLIOBLASTOMA MODEL
Simone P. Niclou (*Luxembourg*)

●Lecture from ASNO

Chairperson: Shin-Ichi Miyatake (*Japan*)

- 10:55 **KN08** INVOLVEMENT OF VEGF-VEGFR SYSTEM IN THE PROGRESSION OF CANCER INCLUDING BRAIN TUMORS.
Masabumi Shibuya (*Japan*)

●Lunchtime Symposium:

TTFIELDS - A Novel Treatment Modality for Brain Tumor Patients

Sponsored by NovoCure Ltd.

Chairperson: Zvi Ram (*Israel*)

- 12:00 **Lsy11** INTRODUCTION
Zvi Ram (*Israel*)
- 12:05 **Lsy12** MECHANISM OF ACTION OF TTFIELDS
Yoram Palti (*Israel*)
- 12:20 **Lsy13** CRITICAL REVIEW OF TTFIELDS LITERATURE
Zvi Ram (*Israel*)
- 12:40 **Lsy14** RESULTS OF NEW PRECLINICAL STUDIES
Eilon Kirson (*Israel*)
- 12:50 **Lsy15** FUTURE CLINICAL TRIALS AND SUMMARY
Roger Stupp (*Switzerland*)

●Chemotherapy, Molecular-Targeted Therapy

Chairperson: Yoshitaka Narita (*Japan*)

- 13:00 **P185** THE POTENTIAL BENEFIT OF NEOADJUVANT AND EXTENDED-ADJUVANT TEMOZOLOMIDE WITH THE STUPP-REGIMEN IN THE TREATMENT OF GLIOBLASTOMA
Ian Brown (*UK*)
- 13:03 **P186** DOSE DENSE ONE WEEK ON/ ONE WEEK OFF TEMOZOLOMIDE IN RECURRENT GLIOMA.
Walter Taal (*Netherlands*)
- 13:06 **P187** CLINICAL TRIAL WITH TEMOZOLOMIDE IN AN ALTERNATING WEEKLY REGIMEN AGAINST RECURRENT MALIGNANT GLIOMAS-A PRELIMINARY REPORT
Akio Asai (*Japan*)
- 13:09 **P188** SAFETY AND EFFICACY OF NEAR-CONTINUOUS DOSE-DENSE TEMOZOLOMIDE (TEGWONDO) FOR RECURRENT GLIOMAS
Herwig Strik (*Germany*)
- 13:12 **P189** PHARMACEUTICAL CONTROL OF TEMOZOLOMIDE CHEMOTHERAPY WITH ORIGINAL LEAFLETS AND ADMINISTRATION HISTORY DATABASE
Sanae Miyano (*Japan*)
- 13:15 **P190** SAFETY AND EFFICACY OF TEMOZOLOMIDE TREATMENT WITH NEWLY DIAGNOSED GLIOBLASTOMA IN JAPAN. A MULTICENTER PHASE II CLINICAL STUDY
Kazuhiko Sugiyama (*Japan*)
- 13:18 **P191** RETROSPECTIVE ANALYSIS OF GLIOBLASTOMA (GBM) PATIENTS TREATED WITH TEMOZOLOMIDE (TMZ)-RADIOTHERAPY FOLLOWED BY TMZ FOR 2 YEARS OR UNTIL PROGRESSION: SURVIVAL ANALYSIS
Alejandro D Muggeri (*Argentina*)
- 13:21 **P192** PSEUDOPROGRESSION OR TUMOR PROGRESSION IN GLIOMAS: WHAT KINDS OF DIAGNOSTIC TOOLS ARE MORE RELIABLE?
Kyung Gi Cho (*Korea*)
- 13:24 **P193** HYPOFRACTIONATED HIGH-DOSE IRRADIATION BY IMRT CONCURRENT WITH PROPHYLACTIC INTRATHECAL CHEMOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA
Toshihiko Iuchi (*Japan*)

- 13:27 **P194** A PILOT SAFETY TRIAL OF HYPOFRACTIONATED RADIATION THERAPY PLUS CONCOMITANT AND ADJUVANT TEMOZOLOMIDE FOR ADULTS WITH GLIOBLASTOMA MULTIFORME
Mizuhiko Terasaki (*Japan*)
- 13:30 **P195** UPFRONT CHEMOTHERAPY FOR GLIOMAS DELETING 1P AND 19Q FOLLOWED BY SECOND-LOOK REMOVAL AND/OR RADIOTHERAPY AT MAXIMUM RESPONSE
Hikaru Sasaki (*Japan*)
- 13:33 **P196** BENEFIT OF CHEMOTHERPY IN ANAPLASTIC ASTROCYTOMAS
Jung Ho Han (*Korea*)
- 13:36 **P197** THERAPY-RELATED MYELODYSPLASTIC SYNDROME FOLLOWING TREATMENT FOR MALIGNANT GLIOMA
Keiichi Sakai (*Japan*)
- 13:39 **P198** TENIPOSIDE AND NIMUSTINE REGIMEN FOR MALIGNANT GLIOMAS WITH O6-METHYLGUANINE-DNA METHYLTRANSFERASE (MGMT) NEGATIVE EXPRESSION: EXPERIENCE OF 18 CASES
Gang Li (*China*)
- 13:42 **P199** SAFETY PROFILE OF CARMUSTINE WAFER TREATMENT IN FIRST LINE TREATMENT OF MALIGNANT GLIOMA WITH CARMUSTINE IMPLANTS FOLLOWED BY CONCOMITANT RADIOCHEMOTHERAPY
Alf Giese (*Germany*)
- 13:45 **P200** THE GROWTH PATTERN OF RECURRENT GLIOBLASTOMA AFTER GLIADEL(TM) WAFER IMPLANTATION IN FIRST RECURRENCES
Dietmar Krex (*Germany*)
- 13:48 **P201** PRE-RADIATION CHEMOTHERAPY WITH ACNU-CDDP IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: A RETROSPECTIVE ANALYSIS
Jung Ho Han (*Korea*)
- 13:51 **P202** A CONCURRENT ASSOCIATION RADIATION THERAPY FOTEMUSTINE FOR NEWLY DIAGNOSED MALIGNANT GLIOMAS, A PHASE II.
Patrick D Beauchesne (*France*)
- 13:54 **P203** TOXICITY PROFILE OF VALPROATE AND ETOPOSIDE METRONOMIC CHEMOTHERAPY
Pournima Navalkele (*USA*)
- 13:57 **P204** COMBINATION THERAPY WITH CARBOPLATIN AND ETOPOSIDE FOR RECURRENT MALIGNANT GLIOMAS
Keiichi Kobayashi (*Japan*)
- 14:00 **P205** PHASE II STUDY OF IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE FOR PATIENTS WITH GLIOBLASTOMA AT FIRST RELAPSE
Tomokazu Aoki (*Japan*)
- 14:03 **P206** PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN PATIENTS WITH BRAINSTEM GLIOMA. PROTOCOL BC-BT-11
Stanislaw R. Burzynski (*USA*)
- 14:06 **P207** TREATMENT OF PRIMARY MALIGNANT GLIOMAS AND MENINGIOMAS WITH RUTA/CALC PHOS
Prasanta Banerji (*India*)
- 14:09 **P208** LEPTOMENINGEAL GLIOMATOSIS IN PATIENTS TREATED WITH BEVACIZUMAB
Maciej M. Mrugała (*USA*)
- 14:12 **P209** RESPONSE TO INTRATHECAL INFUSIONS OF DEPOCYTE IN SECONDARY DIFFUSE LEPTOMENINGEAL GLIOMATOSIS. A CASE REPORT.
Patrick D. Beauchesne (*France*)
- 14:15 **P210** NEW THERAPEUTIC APPROACH FOR BRAIN TUMORS: INTRANASAL ADMINISTRATION OF RAS INHIBITOR MONOTERPENE PERILLYL ALCOHOL.
Clovis Fonseca (*Brazil*)
- 14:18 **P211** CETUXIMAB DOES NOT INFLUENCE SERUM MAGNESIUM HOMEOSTASIS IN PATIENTS WITH GLIOBLASTOMA MULTIFORME TREATED WITH CONCOMITANT RADIOTHERAPY AND TEMOZOLOMIDE
Stefan Rieken (*Germany*)
- 14:21 **P212** A RETROSPECTIVE SINGLE INSTITUTIONAL ANALYSIS OF CILENGITIDE (CGT) AND CHEMOTHERAPY FOR HEAVILY PRE-TREATED RECURRENT GLIOBLASTOMA MULTIFORME (GBM).
Mustafa Khasraw (*Australia*)
- 14:27 **P213** CILENGITIDE MODULATES ATTACHMENT AND VIABILITY OF HUMAN GLIOMA CELLS, BUT NOT SENSITIVITY TO IRRADIATION OR TEMOZOLOMIDE IN VITRO
Gabriele Maurer (*Germany*)

- 14:30 **P214** METABOLIC FACTORS GOVERN THE CYTOTOXIC POTENTIAL OF EGFR INHIBITION IN HUMAN MALIGNANT GLIOMA CELLS
Johannes Rieger (*Germany*)
- Chairpersons:** Michael Prados (*USA*)
Roger Stupp (*Switzerland*)
- 14:40 **O132** RESPONSE ASSESSMENT IN NEURO-ONCOLOGY
David R. Macdonald (*Canada*)
- 15:00 **O133** CREATION OF A CHEMOTHERAPY SIMULATOR TO PREDICT THE CONCENTRATIONS OF SYSTEMICALLY ADMINISTERED CHEMOTHERAPY WITHIN BRAIN TUMOR TISSUE
Stuart A. Grossman (*USA*)
- 15:30 **O134** TARGETING OF THE TYROSINE KINASE RECEPTORS EGFRVIII AND C-MET IN GBM
Terrance G Johns (*Australia*)
- 15:40 **O135** ASSESSMENT OF THE EFFICACY OF ETOPOSIDE AND TEMSIROLIMUS IN AN INTRACRANIAL RODENT MODEL WITH SPECIAL ATTENTION TO THE RELATIONSHIP OF TUMOR AND WHITE CELL P70S6 KINASE ACTIVITY DURING THERAPY
Jeffrey J. Olson (*USA*)
- 15:50 **O136** CDK4/6 SMALL MOLECULE INHIBITOR PD-0332991 DEMONSTRATES ANTI-TUMOR ACTIVITY AGAINST AN INTRACRANIAL GLIOBLASTOMA XENOGRAFT LACKING p16 FUNCTION
Karine Michaud (*USA*)
- 16:00 **O137** RESULTS OF A PHASE IIB STUDY WITH TRABEDERSEN (AP 12009) IN RECURRENT OR REFRACTORY HIGH-GRADE GLIOMA PATIENTS
Ulrich Bogdahn (*Germany*)
- 16:10 **O138** PHASE I STUDY OF TERAMEPROCAL IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS: A NABTT CNS CONSORTIUM TRIAL
Stuart A. Grossman (*USA*)

Break

- Chairpersons:** Victor Levin (*USA*)
Antonio Omuro (*USA*)
- 16:40 **O139** THE COMBINATION OF TEMOZOLOMIDE AND RTA203, A SELECTIVE H⁺-ATPASE INHIBITOR, AUGMENT THE CYTOTOXIC EFFECT ON MALIGNANT GLIOMAS THROUGH BLOCKADE OF AUTOPHAGY
Hiroshi Aoki (*Japan*)
- 16:50 **O140** INTERIM ANALYSIS OF COMBINATION CHEMORADIOOTHERAPY BY MEANS OF TEMOZOLOMIDE (TMZ) AND INTERFERON (IFN) BETA FOR MALIGNANT GLIOMA: MULTICENTER CLINICAL TRIAL (INTEGRA STUDY)
Toshihiko Wakabayashi (*Japan*)
- 17:10 **O141** THE KOREAN EXPERIENCES OF CONCURRENT CHEMORADIOOTHERAPY WITH TEMOZOLOMIDE FOR THE NEWLY DIAGNOSED GLIOBLASTOMA: METAANALYSIS OF PROSPECTIVE STUDY OF FOUR CENTERS
Yong-Kil Hong (*Korea*)
- 17:20 **O142** COMPARISON OF BOLUS AND METRONOMIC CHEMOTHERAPY ON TUMOR CHARACTERISTICS
Akihiko Kondo (*USA*)
- 17:30 **O143** PHASE II TRIAL OF LOW-DOSE CONTINUOUS (METRONOMIC) TREATMENT OF TEMOZOLOMIDE FOR RECURRENT GLIOBLASTOMA
Jong Hyun Kim (*Korea*)
- 17:40 **O144** A CONTINUOUS SCHEDULE OF TMZ FOR GBM AT FIRST RELAPSE MAY OVERCOME THE THERAPEUTIC DISADVANTAGE OF NON-METHYLATED MGMT: RESULTS FROM THE PHASE II RESCUE TRIAL
J. Perry (*Canada*)

●Closing Ceremony

18:00

May 14 (Thu) Room 2
●Pediatric Basic Science I

Sponsored by Pediatric Brain Tumor Foundation

Chairpersons: Annie Huang (*Canada*)
Hideo Takeshima (*Japan*)

- 08:00 **P215** AN EPIGENETIC GENOME-WIDE SCREEN IDENTIFIES THE SFRP FAMILY OF WNT SIGNALING INHIBITORS AS NOVEL TUMOR SUPPRESSOR GENES IN MEDULLOBLASTOMA
Paul N. Kongkham (*Canada*)
- 08:03 **P216** SILENCING OF NEURONAL DIFFERENTIATION GENES REVEALED BY PROFILING THE MEDULLOBLASTOMA EPIMETHYLOGENOME
Adrian Dubuc (*Canada*)
- 08:06 **P217** PEDIATRIC INTRACRANIAL GERM CELL TUMORS OF DIFFERENT PROGNOSIS OUTCOMES AND ETHNIC BACKGROUND INHERIT CHARACTERISTIC EMBRYONIC STEM CELL TRAITS AND MICRORNAOME PROFILES
Hsei-Wei Wang (*Taiwan*)
- 08:09 **P218** THE FREQUENT EXPRESSION OF ARF-BP1 IN PRIMARY INTRACRANIAL GERM CELL TUMORS
Kazuo Washiyama (*Japan*)
- 08:12 **P219** FREQUENT SINGLE NUCLEOTIDE POLYMORPHISM (SNP) OF BCL10 AND ASSOCIATION WITH POOR PROGNOSIS IN PRIMARY INTRACRANIAL GERM CELL TUMORS
Yutaka Hayashi (*Japan*)
- 08:15 **P220** EXPRESSION PROFILES OF MICRORNA IN PEDIATRIC MALIGNANT GLIOMAS
Muh-Lii Liang (*Taiwan*)
- Keynote**
- 08:20 **KN09** EGFR SIGNALING THROUGH AN AKT/SREBP1-DEPENDENT, RAPAMYCIN-RESISTANT PATHWAY SENSITIZES GLIOBLASTOMAS TO ANTI-LIPOGENIC THERAPY
Paul Mischel (*USA*)
- 08:50 **O145** THE MIR-17/92 POLYCYSTRON IS AMPLIFIED AND UP-REGULATED IN SONIC HEDGEHOG-DRIVEN MEDULLOBLASTOMAS AND INDUCED BY N-MYC IN SONIC HEDGEHOG-TREATED CEREBELLAR NEURAL PRECURSORS
Paul A. Northcott (*Canada*)
- 09:05 **O146** EPIGENETIC SILENCING OF KRUPPEL-LIKE FACTOR 4 (KLF4) IN MEDULLOBLASTOMA
Yukiko Nakahara (*Canada*)

●Pediatric Neuro-Oncology II

Sponsored by Pediatric Brain Tumor Foundation

Chairpersons: Mark Kieran (*USA*)
Yutaka Sawamura (*Japan*)

Keynote

- 09:30 **KN10** MANAGEMENT OF YOUNG CHILDREN NEWLY-DIAGNOSED WITH CENTRAL NERVOUS SYSTEM (CNS) EMBRYONAL TUMORS: 18 YEARS OF THREE SEQUENTIAL IRRADIATION-AVOIDING CHEMOTHERAPY STUDIES - THE "HEAD START" PROTOCOLS
Jonathan Finlay (*USA*)
- 09:55 **KN11** THE CHEMOTHERAPEUTIC MANAGEMENT OF LOW GRADE GLIOMAS
Eric Bouffet (*Canada*)
- 10:20 **O147** EPENDYMOMA TREATMENT: AN UPDATE
Stergios Zacharoulis (*UK*)
- 10:40 **O148** MEDULLOBLASTOMA IN INFANTS
Susan Chi (*USA*)
- 11:00 **O149** RECURRENT MEDULLOBLASTOMA- RECENT ADVANCES IN TREATMENT
Sridharan Gururangan (*USA*)

●Lunchtime Seminar

Sponsored by Mitsubishi Tanabe Pharma Corporation

Chairperson: Takamitsu Fujimaki (*Japan*)

- 12:00 **LSe07** HOW NEUROCOGNITIVE OUTCOMES CAN CHANGE CLINICAL TRIAL DESIGN
Elana Farace (*USA*)

●Cognitive Function and Outcome

Chairpersons: Stephen Sands (USA)
Takaaki Yanagisawa (Japan)

Keynote

- 13:00 **KN12** NEUROPSYCHOLOGICAL FUNCTIONING AND OUTCOME FOR BRAIN TUMOR PATIENTS
Stephen Sands (USA)
- 13:30 **O150** MEASURING PERFORMANCE STATUS IN PEDIATRIC BRAIN TUMOR STUDIES -
EXPERIENCE OF THE HIT-GBM-C PROTOCOL
Kamran Mohiuddin (USA)
- 13:40 **O151** DEVELOPMENT OF THE JAPANESE VERSION OF PEDIATRIC QUALITY OF LIFE INVENTORY™ BRAIN
TUMOR MODULE
Iori Sato (Japan)
- 13:50 **O152** A NEW ASSESSMENT TOOL FOR MEASURING NEUROLOGICAL AND BEHAVIORAL FUNCTION ACROSS
LIFESPAN: THE NIH TOOLBOX
Jin-Shei Lai (USA)
- 14:00 **O153** DETAILED PROSPECTIVE NEUROPSYCHOLOGICAL, ACTIVITY OF DAILY LIVING AND ENDOCRINE
FUNCTION ASSESSMENT IN CHILDREN WITH CRANIOPHARYNGIOMA TREATED WITH STEREOTACTIC
CONFORMAL RADIOTHERAPY
Debnarayan Dutta (India)
- 14:10 **O154** MANAGING CHALLENGING BEHAVIOURS AFTER BRAIN CANCER: A RESOURCE FOR PATIENTS, CARERS
AND HEALTH PROVIDERS
Teresa Simpson (Australia)
- 14:20 **O155** PATIENT FUNCTIONAL STATUS IS STRONGEST CORRELATE OF CHALLENGING BEHAVIOUR AFTER BRAIN
TUMOUR
Eng-Siew Koh (Australia)
- 14:30 **P221** STRESS LEVELS AMONG PARENTS OF CHILDHOOD BRAIN TUMOR SURVIVORS
Jin-Shei Lai (USA)
- 14:33 **P222** MULTI-TIERED INTERVENTION STUDY FOR PATIENTS, CARERS AND HEALTH PROVIDERS TO ADDRESS
CHALLENGING BEHAVIOURS AFTER BRAIN TUMOUR
Eng-Siew Koh (Australia)
- 14:36 **P223** KNOWLEDGE AND ATTITUDES ON THE DIAGNOSIS, TREATMENT AND PROGNOSIS AMONG PATIENTS
WITH BRAIN TUMOR AND THEIR CAREGIVERS IN A TERTIARY HOSPITAL
Natasha L. Fabiana (Philippines)
- 14:39 **P224** MANAGEMENT OF PRIMARY MALIGNANT BRAIN TUMORS DURING PREGNANCY
Julette F. Batara (Philippines)

●Pediatric Basic Science II

Chairpersons: Catherine Godfraind (Belgium)
Kazuo Washiyama (Japan)

- 14:50 **O156** MOUSE MODELS OF CNS EMBRYONAL TUMORS
Hiroyuki Momota (Japan)
- 15:00 **O157** MULTIPLE RECURRENT GENETIC EVENTS CONVERGE ON CONTROL OF HISTONE LYSINE METHYLATION
IN MEDULLOBLASTOMA
Paul A. Northcott (Canada)
- 15:10 **O158** CLONAL SELECTION AND PARALLEL EVOLUTION DEFINE THE HIERARCHICAL STRUCTURE OF
METASTATIC MEDULLOBLASTOMA
Xiaochong Wu (Canada)
- 15:20 **O159** INTEGRATED GENE EXPRESSION AND COPY-NUMBER ANALYSES IDENTIFY AGGRESSIVE PEDIATRIC
CENTRAL NERVOUS SYSTEM PRIMITIVE NEURO-ECTODERMAL TUMORS
Annie Huang (Canada)
- 15:30 **O160** GENOMIC PROFILING OF INTRACRANIAL GERM CELL TUMORS WITH SINGLE NUCLEOTIDE
POLYMORPHISM ARRAY
Keita Terashima (USA)
- 15:40 **O161** PATHWAYS AND GENES ASSOCIATED WITH EPENDYMOMA LOCATION, GRADE AND SUBGROUPS.
Catherine Godfraind (Kingdom of Belgium)

- 16:00 **O162** GENETIC PROFILING OF PEDIATRIC NON-EPENDYMAL GLIOMAS ASSOCIATED WITH TEMOZOLOMIDE RESISTANCE
Taketo Ezaki (*Japan*)
- 16:10 **O163** THE MAPK PATHWAY IS ALTERED IN THE MAJORITY OF PILOCYTIC ASTROCYTOMAS
David T.W. Jones (*UK*)

May 14 (Thu) Room 3

●Poster Presentations: Basic Science

Chairperson: Tomoyuki Koga (*Japan*)

- 08:00 **P225** CANCER STEM CELLS FROM GLIOBLASTOMA MULTIFORME PATIENTS
Wen-Yu Cheng (*Taiwan*)
- 08:03 **P226** CHARACTERIZATION OF CANCER STEM-LIKE CELLS DERIVED FROM HUMAN GLIOBLASTOMAS
Masamichi Takahashi (*Japan*)
- 08:06 **P227** CHARACTERIZATION OF CANCER STEM CELLS IN HUMAN GLIOBLASTOMAS
Akihiro Inoue (*Japan*)
- 08:09 **P228** CHARACTERIZATION OF TUMOR STEM CELLS ISOLATED FORM HUMAN GLIOBLASTOMA MULTIFORME
Kiminobu Sugaya (*USA*)
- 08:12 **P229** STAT3 SERINE727 ACTIVATION IN GLIOMA CANCER STEM CELLS
Akio Soeda (*USA*)
- 08:15 **P230** ENHANCEMENT OF STEM-LIKE GLIOMA NEUROSPHERE RADIORESPONSE BY GEFITINIB: BY INCREASED DNA DAMAGE AND REDUCED DNA REPAIR CAPACITY
Khong Bee Kang (*Singapore*)
- 08:18 **P231** INHIBITION OF TUMOR GROWTH AND ANGIOGENESIS BY TARGETING CXCL12/CXCR4 AXIS IN STEM CELL-LIKE GLIOMA CELLS
Xiu-wu Bian (*China*)
- 08:21 **P232** CULTIVATION AND IDENTIFICATION OF THE CELLS FROM CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS AND ITS STEM CELLS ORIGIN
Rong Xie (*China*)
- 08:24 **P233** SCREEN AND IDENTIFY THE CRITICAL PROTEINS OF CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMA TUMOR CELLS USING ON-LINE CAPILLARY 2D-HPLC COMBINED WITH LTQ-ORBITRAP MS
Rong Xie (*China*)
- 08:30 **P234** NOTCH1 INDUCES MORE EXPRESSION OF DLL1 IN U251MG GLIOMA CELL LINE
You P. You (*China*)
- 08:33 **P235** HEDGEHOG PATHWAY AND GLIOMAGENESIS
Tatsuya Takezaki (*Japan*)
- 08:36 **P236** THE FUNCTIONAL ANALYSIS OF A NOVEL KDR (VEGFR II)-PDGFR-ALPHA FUSION GENE IN GLIOBLASTOMA: FROM DISCOVERY TO CLINICAL APPLICATION
Tatsuya Ozawa (*USA*)
- 08:39 **P237** ISOLATION AND CHARACTERIZATION OF AN N-LINKED OLIGOSACCHARIDE THAT IS INCREASED IN GLIOBLASTOMA TISSUE AND CELL LINE.
Ryuya Yamanaka (*Japan*)
- 08:42 **P238** INHIBITION OF GLIOMA PROLIFERATION BY MODIFIED P53 PROTEIN FUSED WITH PROTEIN TRANSDUCTION DOMAINS
Hiroyuki Michiue (*Japan*)
- 08:45 **P239** EXPRESSION OF THE LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN-1 (LAMP-1) IN ASTROCYTOMAS
Stine S. Jensen (*Denmark*)
- 08:48 **P240** EVALUATION OF ELK-1 ACTIVATION BY PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY IN GLIOBLASTOMA
Melike Mut (*Turkey*)
- 08:51 **P241** ANTINEOPLASTONS INHIBIT MCM COMPLEX IN GLIOBLASTOMA CELLS
Sonali Patil (*USA*)

- 08:54 **P242** ENHANCED EXPRESSION OF NADPH OXIDASE NOX4 IN HUMAN GLIOMAS AND ITS ROLES IN CELL PROLIFERATION AND SURVIVAL
Tadahisa Shono (*Japan*)
- 08:57 **P243** EXPRESSION PATTERN OF EGFRS, INTEGRINS, AND RELATED MOLECULES IN HUMAN GLIOBLASTOMA VERSUS INTRACEREBRAL LUNG ADENOCARCINOMA METASTASIS
Almos Klekner (*Hungary*)
- 09:00 **P244** INHIBITION OF LRIG3 GENE EXPRESSION VIA RNA INTERFERENCE MODULATES THE PROLIFERATION, CELL CYCLE, CELL APOPTOSIS, ADHESION AND INVASION OF GLIOBLASTOMA CELL
Dongsheng Guo (*China*)
- 09:03 **P245** PROMYELOCYTIC LEUKEMIA PROTEIN INDUCES APOPTOSIS BY THE REPRESSION OF NF κ B ACTIVATION IN GLIOBLASTOMA CELLS.
Kazuhito Matsuzaki (*Japan*)
- 09:06 **P246** THE CELLULAR ONCOGENE ETS-1 COUNTERACTS P53 TUMOUR SUPPRESSOR ACTIVITY BY AFFECTING THE LEVEL OF P53 PROTEIN.
Ella L. Kim (*Germany*)
- 09:09 **P247** COOPERATIVE CYTOTOXICITY BY HDAC INHIBITORS AND RTKIS: INDUCTION OF CX43 IN GBM CELLS
Thomas Asklund (*Spain*)
- 09:12 **P248** A MDR1 (ABCB1) GENE SINGLE NUCLEOTIDE POLYMORPHISM PREDICTS OUTCOME OF TEMOZOLOMIDE TREATMENT IN GLIOBLASTOMA PATIENTS
Dietmar Krex (*Germany*)
- 09:15 **P249** DIVERSITY OF DNA DAMAGE RESPONSE OF ASTROCYTES AND GLIOBLASTOMA CELL LINES WITH VARIOUS P53 STATUS TO TREATMENT WITH ETOPOSIDE AND TEMOZOLOMIDE
Yuichi Sato (*Japan*)
- 09:18 **P250** THE DECREASED EXPRESSION OF GANP IS ASSOCIATED WITH CHROMOSOMAL INSTABILITY IN MALIGNANT GLIOMAS
Kazutaka Ohta (*Japan*)
- 09:21 **P251** ELK4 NEUTRALISATION SENSITISES HIGH GRADE GLIOMA TO APOPTOSIS THROUGH DOWN REGULATION OF THE ANTI-APOPTOTIC PROTEIN MCL-1
Brett W Stringer (*Australia*)
- 09:24 **P252** XCT AS A POTENTIAL MOLECULAR TARGET IN GLIOBLASTOMA MULTIFORME
Hiroshi Nawashiro (*Japan*)
- 09:27 **P253** A NOVEL MMAC/PTEN GENE MUTATION IN A GBM PATIENT
Gulsah Cecener (*Turkey*)

Break

Chairperson: Kenji Wakiya (*Japan*)

- 09:40 **P254** ATTRACTION OF HEMATOPOIETIC PROGENITOR CELLS BY EXPERIMENTAL GLIOMAS IN VIVO: TOWARDS A CELL-BASED THERAPY FOR MALIGNANT GLIOMAS?
Ghazaleh Tabatabai (*Germany*)
- 09:43 **P255** OLIGODENDROGLIOMAS WITH LOH 1P/19Q: IDENTIFYING GENES ASSOCIATED WITH THERAPEUTIC SENSITIVITY
Cathy A Payne (*Australia*)
- 09:46 **P256** ASSOCIATION OF 7Q34 COPY NUMBER GAINS AND KIAA1549-BRAF GENE FUSIONS WITH JUVENILE PILOCYTIC ASTROCYTOMA
J.Graeme Hodgson (*USA*)
- 09:49 **P257** IDH-1 MUTATIONS ARE FREQUENT IN LOW GRADE GLIOMA AND DO NOT CORRELATE WITH OUTCOME TO TEMOZOLOMIDE CHEMOTHERAPY
Erik-Jan Dubbink (*Netherlands*)
- 09:52 **P258** PPAR- γ ACTIVATORS: OFF-TARGET AGAINST TGF- β MEDIATED GLIOMA CELL MIGRATION AND BRAIN INVASION
Sebastian M. Seufert (*Germany*)
- 09:55 **P259** TIGHT JUNCTION PROTEIN OCCLUDIN IN HUMAN BRAIN TUMORS: RADIOLOGICAL CORRELATION AND PROGNOSTIC IMPLICATION ON THE SURVIVAL
Choong-Hyun Kim (*Korea*)
- 09:58 **P260** EXPRESSION OF THE TIMP-1 INTERACTING CELL SURFACE PROTEIN CD63 IN ASTROCYTOMAS
Charlotte Aaberg-Jessen (*Denmark*)

- 10:01 **P261** MOLECULAR VARIATIONS IN TUMOR-HOST INTERACTIONS BETWEEN INVASIVE AND ANGIOGENIC PHENOTYPE IN HIGH GRADE GLIOMAS
Uros Rajcevic (*Luxembourg*)
- 10:04 **P262** MULTI-MODAL IMAGING OF ACUTE AND CHRONIC UP-REGULATION OF HYPOXIA-INDUCIBLE FACTOR-1 (HIF-1) IN TUMORS
Tadashi Miyagawa (*Japan*)
- 10:07 **P263** RELATIONSHIP BETWEEN ABC TRANSPORTER PROTEINS AND VASCULOGENESIS IN GLIOBLASTOMAS
Keisuke Miyake (*Japan*)
- 10:10 **P264** HISTONE DEACETYLASE INHIBITOR, VALPROIC ACID INHIBITS GLIOMA ANGIOGENESIS IN VITRO AND IN VIVO IN THE BRAIN
Satoru Osuka (*Japan*)
- 10:13 **P265** THE P14ARF TUMOR SUPPRESSOR INHIBITS GLIOMA-INDUCED ANGIOGENESIS BY A NOVEL MDM2/SP1/TIMP3 SIGNALING AXIS
Erwin G Van Meir (*USA*)
- 10:16 **P266** DICER-REGULATED MICRORNAS 222 AND 339 PROMOTE RESISTANCE OF CANCER CELLS TO CYTOTOXIC T-LYMPHOCYTES BY DOWN-REGULATING ICAM-1 EXPRESSION
Ryo Ueda (*USA*)
- 10:19 **P267** HYPOXIA-INDUCED STAT3 ACTIVITY CONTRIBUTES THE HIF-1, VEGF, MMP2 AND TWIST EXPRESSION IN HUMAN GLIOBLASTOMA, WHICH INDUCE ANGIOGENESIS AND CELL MIGRATION.
Cancelled
- 10:22 **P268** NOVEL MONOCLONAL ANTIBODY 13R2.C3 AGAINST IINTERLEUKIN 13 RECEPTOR ALPHA-2 REVEALS A SPECIFIC AND MORE WIDE-SPREAD EXPRESSION OF THE RECEPTOR IN VARIOUS BRAIN TUMORS
Waldemar Debinski (*USA*)
- 10:25 **P269** SYNERGISTIC EFFECT OF HUMAN IFN-BETA AND TMZ ON MALIGNANT GLIOMA CELL LINES
Atsuo Yoshino (*Japan*)
- 10:28 **P270** THE ROLE OF CHEMOKINE SDF-1/CXCR4/CXCR7 FOR GLIOBLASTOMA ANGIOGENESIS AND GLIOBLASTOMA DERIVED ENDOTHELIAL CELLS
Shingo Takano (*Japan*)
- 10:31 **P271** SOLUBLE CD70 CONFERS AN IMMUNE-MEDIATED SURVIVAL ADVANTAGE IN EXPERIMENTAL GLIOBLASTOMA
James Miller (*Germany*)
- 10:34 **P272** ABERRANT HYPERMETHYLATION OF CPG ISLANDS PROFILE OF CELL CYCLE REGULATORY GENES IN MALIGNANT ASTROCYTOMAS
Takashi Ohta (*Japan*)
- 10:37 **P273** AN IN VITRO STUDY OF SELECTED SYNTHETIC CHALCONE ANALOGUES ACTIVITY AGAINST BEN-MEN-1 MENINGIOMA CELL LINE
Igor Sulla (*Slovak*)
- 1040 **P274** NEW CCM1 GENE MUTATIONS IN CHINESE SPORADIC INTRACRANIAL CAVERNOUS ANGIOMA PATIENTS
Rong Xie (*China*)
- 10:43 **P275** THE FUNCTIONAL ROLE OF EIF4E IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Daisuke Muta (*Japan*)
- 10:55 **P276** IS IT TOTAL REMOVAL OF GLIOBLASTOMA POSSIBLE? - TUMOR CELL INFILTRATION FROM AUTOPSY BRAIN
Yoshihiro Numa (*Japan*)
- 10:58 **P277** CLINICAL SIGNIFICANCE OF VASCULOGENIC MIMICRY IN HUMAN GLIOMAS
Zhongping Chen (*China*)
- 1101 **P278** VALIDATION OF PROGNOSTIC AND THERAPEUTIC WORTH OF MOLECULAR MARKERS BY ROUTINE TOOLS IN DIAGNOSTIC AND CLINICAL NEUROPATHOLOGY: A STUDY OF 193 GLIOBLASTOMAS.
Bianca Pollo (*Italia*)
- 11:04 **P279** OLIGODENDROGLIAL TUMOR CLASSIFICATION: PHENOTYPE VS GENETIC SIGNATURE
Horacio Martinetto (*Argentina*)
- 11:07 **P280** HISTOLOGIC ANAPLASIA IN SPORADIC AND NF1-ASSOCIATED PILOCYTIC ASTROCYTOMAS PREDICTS UNFAVORABLE BEHAVIOR
Fausto J. Rodriguez (*USA*)
- 11:10 **P281** APPLICATION OF A CYTOGENETIC PROGRESSION SCORE (GPS), TUMOR LOCATION AND GENETIC PROGRESSION IN MENINGIOMAS: HACETTEPE EXPERIENCE
Melike Mut (*Turkey*)

- 11:13 **P282** TARGETING THE TUMOR STROMA A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS
Jian Wang (Norway)
- 11:16 **P283** THERAPEUTIC EFFICACY OF A POLYMERIC MICELLAR DOXORUBICIN INFUSED BY CONVECTION-ENHANCED DELIVERY AGAINST INTRACRANIAL 9L BRAIN TUMOR MODELS
Yoji Yamashita (Japan)
- 11:19 **P284** LABEL-FREE DIFFERENTIATION OF INDIVIDUAL HUMAN GLIOMA CELLS BY OPTICAL FTIR SPECTROSCOPIC IMAGING
Matthias Kirsch (Germany)
- 11:22 **P285** APPLICATION OF MULTIPLE-STAGE TANDEM IMAGING MASS SPECTROMETRY TO THE EVALUATION OF LIPIDS IN A RAT BRAIN C6 GLIOMA MODEL
Shinichiro Koizumi (Japan)
- 11:25 **P286** SPECTROSCOPIC IMAGING OF CEREBRAL MICROMETASTASES IN A MURINE MODEL
Matthias Kirsch (Germany)
- 11:28 **P287** SIGNIFICANCE OF NMR BASED METABOLOMICS (METABOLOME) FOR THE PREDICTION OF MALIGNANT TYPE MENINGIOMA USING THE ANALYSIS OF WATER AND LIPID-SOLUBLE METABOLITES
Hiroshi Takahashi (Japan)
- 11:31 **P288** ROLE OF PROTEOMIC STUDY OF CSF AS A DIAGNOSTIC TOOL IN THE PATIENTS WITH MENINGIOMAS
Jae ho Kim (Korea)
- 11:34 **P289** IL-6 IN MENINGIOMA; EXPRESSION IS CORRELATED WITH PERITUMORAL EDEMA AND VEGF
Cancelled
- 11:37 **P290** ANTITUMOR EFFECT OF HUMANIZED ANTI-IL-6 RECEPTOR ANTIBODY (TOCILIZUMAB) ON GLIOMA CELL PROLIFERATION
Mareina Kudo (Japan)
- 11:40 **P291** THE PLASMA CONCENTRATION OF ET-1 IN THE BRAIN TUMORS
Ann-Shung Lieu (Taiwan)
- 11:43 **P292** PLASMA IGF LEVELS CORRELATE WITH DIAGNOSIS AND RESPONSE TO THERAPY IN GLIOMA PATIENTS
Yi Lin (China)
- 11:46 **P293** DELETION OF PTEN IN CLIVAL CHORDOMAS
Dae-Hee Lee (USA)
- Display only **P294** PROMOTER METHYLATION PROFILES OF SIX TUMOR-RELATED GENES IN VARIOUS BRAIN TUMORS
Lu-Ting Kuo (Taiwan)

●Lunchtime Symposium

Chairperson: Chen-Nen Chang (Taiwan)

- 12:00 **LSy16** HIGH-PRECISION RADIOTHERAPY FOR CNS TUMORS USING NEW HIGH-TECH MACHINES
Yuta Shibamoto (Japan)

●Radiation Oncology

Chairpersons: Rakesh Jalali (India)
Normand Laperriere (Canada)

- 13:00 **O164** PATIENT-SPECIFIC VIRTUAL CONTROLS CAN BE USED TO SIMULATE AND PREDICT RESPONSE TO RADIATION THERAPY IN INDIVIDUAL GLIOBLASTOMA PATIENTS
Kristin R Swanson (USA)
- 13:10 **O165** CAN WHOLE BRAIN IRRADIATION (WBI) REALLY IMPROVE NEUROLOGICAL STATUS AND QUALITY OF LIFE OF PATIENTS WITH BRAIN METASTASES (BM)? A PROSPECTIVE MULTICENTER ANALYSIS OF THE BARCELONA GLIOMA GROUP. FINAL RESULTS
Salvador Villa (Israel)
- 13:20 **O166** INTENSITY MODULATED RADIATION THERAPY FOR CRANIOSPINAL IRRADIATION USING HELICAL TOMOTHERAPY: FROM PLANNING TO DELIVERY
Tejpal Gupta (India)
- 13:30 **O167** AGE AND RADIOTHERAPY DOSES TO LEFT TEMPORAL LOBE PREDICT NEUROCOGNITIVE OUTCOMES IN YOUNG PATIENTS WITH BENIGN AND LOW GRADE BRAIN TUMOURS: DATA FROM A PROSPECTIVE TRIAL OF STEREOTACTIC CONFORMAL RADIOTHERAPY
Rakesh Jalali (India)
- 13:40 **O168** CARBON ION RADIATION THERAPY FOR PAEDIATRIC PATIENTS AND YOUNG ADULTS TREATED FOR TUMORS OF THE SKULL BASE
Stephanie E Combs (Germany)

- 14:00 **O169** PSEUDOPROGRESSION IN BORON NEUTRON CAPTURE THERAPY
Shin-Ichi Miyatake (*Japan*)
- 14:10 **O170** DIAGNOSIS AND TREATMENT OF RADIATION NECROSIS IN THE BRAIN
Shin-Ichi Miyatake (*Japan*)
- 14:20 **P295** SHORT COURSE OF RADIOTHERAPY AND CONCOMITANT TEMOZOLOMIDE IN PATIENTS AFFECTED WITH GLIOBLASTOMA WITH V-VI PROGNOSTIC CLASSES. A PILOT STUDY
Salvador Villa (*Spain*)
- 14:23 **P296** ASSESSMENT OF ¹¹C-METHIONINE PET CHANGES FOR MONITORING THERAPEUTIC RESPONSE FOLLOWING SIMULTANEOUS INTEGRATED BOOST TECHNIQUE FOR GLIOBLASTOMA MULTIFORME
Kazuhiro Miwa (*Japan*)
- 14:26 **P297**
Cancelled RECURRENCE PATTERN AFTER [(18)F]FLUOROETHYLTYROSINE- POSITRON EMISSION TOMOGRAPHY-GUIDED RADIOTHERAPY FOR HIGH-GRADE GLIOMA.
- 14:29 **P298** RHABDOMYOSARCOMA AS A LATE COMPLICATION OF STEREOTACTIC RADIOTHERAPY IN THE PATIENT WITH NEUROFIBROMATOSIS TYPE 2
Dusica Babovic-Vuksanovic (*USA*)
- 14:32 **P299** RADIATION-INDUCED CEREBRAL CAVERNOUS HEMANGIOMAS IN ADULTS.
Alexander Lossos (*Israel*)
- 14:35 **P300** HEMATOTOXICITY OF CRANIOSPINAL IRRADIATION IN ADULT PATIENTS
Katarzyna Elandt (*Austria*)
- 14:38 **P301** INSPECTION ABOUT RECURRENCE AND PROGRESSING DEMENTIA AFTER WBRT TO METASTATIC BRAIN TUMOR - PROBLEM PRESENTATION AGAINST WBRT -
Akio Asai (*Japan*)
- 14:41 **P302** NOVALIS SHAPED BEAM RADIOSURGERY FOR CRANIAL AND SPINAL TUMORS: 8 YEARS OF EXPERIENCE IN KOREA
Hae-Won Gu (*Korea*)
- 14:44 **P303** ULTRAFRACTIONATED RADIATION THERAPY (3 DOSES PER DAY) FOR INOPERABLE GLIOBLASTOMAS. A NEW AND PROMISING REGIMEN.
Patrick D Beauchesne (*France*)
- 14:47 **P304** STEREOTACTIC RADIOSURGERY (SRS) IN RECURRENT HIGH-GRADE GLIOMA
Felix Bokstein (*Israel*)
- 14:50 **P305** TREATED WITH CYBERKNIFE STEREOTACTIC RADIOSURGERY: TWO CYBERKNIFE CENTERS EXPERIENCE
Da-Tong Ju (*Taiwan*)
- 14:53 **P306** PERITUMORAL EDEMA AFTER CYBERKNIFE RADIOSURGERY FOR MENINGIOMA: REPORT OF TWO CASES AND REVIEW OF LITERATURE.
Cheng-Ta Hsieh (*Taiwan*)
- 14:56 **P307** PRELIMINARY RESULTS OF INITIALLY TRATED PATIENTS-FEASIBILITY OF APPLYING THE SYNERGY-S SYSTEM FOR STEREOTACTIC IRRADIATION SPINAL TUMORS
Andrew A. Kanner (*Israel*)
- 14:59 **P308** DOSE-VOLUME ANALYSIS OF WHOLE VENTRICULAR IRRADIATION BY PROTON BEAM COMPARING WITH INTENSITY MODULATED RADIOTHERAPY AND STANDARD PHOTON THERAPY
Hiroshi Fuji (*Japan*)
- 15:02 **P309** IN VIVO BIODISTRIBUTION OF BORON AFTER INTRAVENOUS 4-DIHYDROXYBORYLPHENYLALANINE-FRUCTOSE (BPA-F) INFUSION IN MENINGIOMA AND SCHWANNOMA: A FEASIBILITY STUDY FOR BORON NEUTRON CAPTURE THERAPY(BNCT)
Merja E Kallio (*Finland*)
- 15:05 **P310** CLINICAL RESULTS OF MODIFIED BORON NEUTRON CAPTURE THERAPY FOR MALIGNANT GLIOMA
Shinji Kawabata (*Japan*)
- 15:08 **P311** BRAIN TUMORS BRACHYTHERAPY BY USING RIGID IR192 CATHETER
Arturas Sitkauskas (*Republic of Lithuania*)

●Primary Central Nervous System Lymphoma

Sponsored by Toray Medical Co., Ltd.

Chairpersons: Norio Arita (*Japan*)
Brian Patrick O'Neill (*USA*)

Keynote

- 15:20 **KN13** PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Antonio Omuro (*USA*)

- 15:50 **O171** BRIEF REPORT: ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (ACGH) CONFIRMS FLUORESCENT IN SITU HYBRIDIZATION (FISH) 6Q DELETION IN POOR-PROGNOSIS DIFFUSE LARGE B-CELL, CD20 POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL).
Brian Patrick O'Neill (*USA*)
- 16:00 **O172** PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS DERIVE FROM B-CELL IN TRANSITION STAGE FROM GERMINAL CENTER B-CELL TO POST GERMINAL CENTER B-CELL.
Manabu Kinoshita (*Japan*)
- 16:10 **O173** NEUROLYMPHOMATOSIS (NL) IN HEMATOLOGIC MALIGNANCIES: AN INTERNATIONAL PRIMARY CNS LYMPHOMA COLLABORATIVE GROUP REPORT.
Sigal Grisariu (*Israel*)
- 16:30 **O174** SALVAGE CHEMOTHERAPY WITH TEMOZOLOMIDE IN REFRACTORY OR RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Keishi Makino (*Japan*)
- 16:40 **P312** IMAGING FEATURES IN PARENCHYMAL LYMPHOMATOUS MASSES IN BRAIN: PRIMARY CNS LYMPHOMA OR SYSTEMIC INVOLVEMENT OF THE BRAIN?
Melike Mut (*Turkey*)
- 16:43 **P313** LONG-TERM SURVIVAL IN PRIMARY CNS LYMPHOMA TREATED BY HIGH-DOSE METHOTREXATE MONOCHEMOTHERAPY: ROLE OF STAT6 ACTIVATION AS PROGNOSTIC DETERMINANT
Seung-Ho Yang (*Korea*)
- 16:46 **P314** TREATMENT FOR PRIMARY CNS LYMPHOMA WITH HIGH-DOSE MTX AND SALVAGE THERAPY WITH ESHAP
Hiroshi Kanno (*Japan*)
- 16:49 **P315** TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA WITH TEMOZOLOMIDE, VINCRISTINE, DOXORUBICIN, PREDNISONE AND RITUXIMAB
Yi Lin (*China*)
- 16:52 **P316** INTRAVENOUS RITUXIMAB COMBINED WITH TEMOZOLOMIDE AS A SECOND LINE THERAPY FOR CD20 POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM MALIGNANT LYMPHOMA
Akira Matsuno (*Japan*)
- 16:55 **P317** MAINTENANCE THERAPY USING RITUXIMAB FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Tomotsugu Ichikawa (*Japan*)
- 16:59 **P318** DIAGNOSIS AND MANAGEMENT OF SPINAL EXTRADURAL NON-HODGKIN LYMPHOMA: ANALYSIS OF THREE CASES AND REVIEW OF THE LITERATURE
Chi-tun Tang (*Taiwan*)